



WITNESS STATEMENT OF PROFESSOR DAN LUBMAN

I, Professor Daniel Ian Lubman PhD, FRANZCP, FChAM, Executive Clinical Director of Turning Point, Eastern Health and Professor of Addiction Studies and Services, Monash University, of 110 Church St, Richmond, say as follows:

- 1 I am making this statement in my own capacity.
- 2 I make this statement on the basis of my own knowledge, save where otherwise stated. Where I make statements based on information provided by others, I believe such information to be true.

BACKGROUND

Qualifications and experience

- 3 I hold the following qualifications:
 - (a) Bachelor of Science (BSc Hons);
 - (b) Bachelor of Medicine and Bachelor of Surgery (MB ChB);
 - (c) Doctor of Philosophy (PhD);
 - (d) Fellowship of the Royal Australian and New Zealand College of Psychiatrists (**RANZCP**); and
 - (e) Fellowship of the Australasian Chapter of Addiction Medicine (AChAM).
- 4 I have worked across mental health and drug treatment settings in the UK and Australia. My current roles are:
 - (a) Executive Clinical Director, Turning Point, Eastern Health;
 - (b) Professor of Addiction Studies and Services, Eastern Health Clinical School, Monash University; and
 - (c) Director, Monash Addiction Research Centre, Monash University.
- 5 Prior to joining Turning Point in 2010, I held the following appointments:
 - (a) Associate Professor, Centre for Youth Mental Health, University of Melbourne and Consultant Psychiatrist, Orygen Youth Health (2008-2010);
 - (b) Nauma Licht Research Fellow and Senior Lecturer, Department of Psychiatry, University of Melbourne and Consultant Psychiatrist, Orygen Youth Health (2003-2008); and

- (c) Nauma Licht Research Fellow and Consultant Psychiatrist, Royal Melbourne Hospital and Melbourne Neuropsychiatry Centre (2002-2003).
- 6 My research is wide-ranging and includes investigating the harms associated with alcohol, drugs and gambling, the impact of alcohol and drug use on brain function, the relationship between substance use, gambling and mental disorder, as well as the development of targeted telephone, online and face-to-face intervention programs within school, primary care, mental health and drug treatment settings.
- 7 I have published over 500 reports, peer-reviewed scientific papers and book chapters, and was Chair of the RANZCP's Faculty of Addiction Psychiatry for over a decade. I regularly provide policy advice and community comment and sit on numerous government expert committees.
- 8 Amongst others, I have received the following awards:
- (a) *Research into Action* (Exploring Men's Risky Drinking), VicHealth Award (2019);
 - (b) *Outstanding Achievement Award*, International Society of Addiction Medicine (2018);
 - (c) *Senior Scientist Award*, Australasian Professional Society on Alcohol and Other Drugs (2017);
 - (d) *Excellence in Prevention and Education* (MAKINGtheLINK). National Alcohol and Drug Awards (2017); and
 - (e) *Senior Research Award*, Royal Australian and New Zealand College of Psychiatrists (2016).
- 9 Attached to this statement and marked 'DL-1' is a copy of my curriculum vitae.

Current role and responsibilities.

- 10 Turning Point is a national addiction treatment centre dedicated to providing high quality, evidence-based treatment to people adversely affected by alcohol, drugs and gambling, integrated with world-leading research and education.
- 11 In my role as Executive Clinical Director and Professor of Addiction Studies and Services, I provide strategic, clinical and academic leadership across Turning Point, Eastern Health and Monash University. This involves ensuring the delivery of high quality clinical services, developing research and teaching programs that build new knowledge and competencies in the addiction field, and providing policy and practice advice on addiction issues to government and relevant service sectors, as well as expert comment to the community.

QUESTIONS FOR THE PANEL

Question 1: What does a best practice service response and consumer experience entail for adults and young people with co-occurring mental illness and problematic alcohol and other drug use?

Preliminary issues

- 12 Before addressing the issue of best practice responses, it is important to consider two broader issues.
- 13 Firstly, 'problematic drug and alcohol use' is a non-specific term that requires definition. 'Problematic drug and alcohol use' could simply refer to single use of an illicit drug, which would capture approximately 15.6% of Australians aged 14+ over the past 12 months, or 42.6% over their lifetime, according to the Australian Institute of Health and Welfare (AIHW). It could also mean drinking above the National Health and Medical Research Council's (NHMRC) alcohol guidelines of no more than 4 standard drinks on any one occasion at least once a month, encompassing 25.5% of Australians aged 14+ (AIHW). The non-specific and undefined nature of this term is problematic in its own right, and could be misconstrued as a prejudicial view of someone else's alcohol or drug consumption. It is my view that the term 'substance use disorder', as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V), should be used, reflecting that we are discussing a specific category of mental health disorder.
- 14 The term 'problematic drug and alcohol use' is reflective of how the current health system typically views and addresses substance use disorders — not as legitimate health conditions, or even mental disorders, but something that is self-inflicted and trivialised. It is akin to dismissing depression as a genuine health disorder by saying that people have 'problematic mood', a term that minimises the suffering experienced and insinuates a level of blame, weakness or poor self-control. The failure to address substance use disorders by their proper name enables them to be dismissed as a health issue by both the health system, including mental health providers, and the community. It is also reflective of evidence demonstrating that substance use disorders are one of the most highly stigmatised health conditions. Language and terminology is key, as evidenced by the enormous investment in changing community understanding and narratives around depression, suicide and youth mental health over the past decade. By failing to use the appropriate terminology, it perpetuates the belief that substance use disorders are not health (or even mental health) issues, allowing them to be dismissed from any discussions around health reform and receiving adequate attention and resourcing.

- 15 Secondly, it is wrong to conceptualise substance use disorders as separate from mental health. Substance use disorders are mental health disorders, and have been classified as such for decades. The World Health Organisation classification of mental health disorders in the International Statistical Classification of Diseases and Related Health Problems 10th edition (**ICD-10**) clearly defines substance use disorders as mental health disorders. Likewise the DSM-V, published by the American Psychiatric Association in 2013 and adopted widely across the world by health systems, clinicians and researchers, also defines substance use disorders as mental health disorders.
- 16 In contrast, when we consider service provision, substance use disorders are almost invariably considered outside the context of mental health. This has implications for how we approach the treatment of substance use disorders and equip the community to deal with them. For example, Australian national and state policy documents which discuss the burden of disease note the substantial burden of mental disorders. They highlight that the most common mental disorders are anxiety, depression and substance use disorders. Yet, when service delivery is conceptualised and commissioned, substance use disorders are not considered as mental health disorders and are segregated and siloed in terms of service and system responses.
- 17 There is an enormous evidence base available on the effective treatment of substance use disorders, both locally and internationally. However, the failure to recognise substance use disorders as legitimate health disorders results in funding of services and systems that are typically divorced from mainstream healthcare, and not adequately resourced to deliver gold standard evidence-based treatments and models of care.
- 18 Throughout this statement, my comments relate specifically to substance use disorders and their relationship with mental illness. However, it is important to note that most of the issues that I raise in terms of terminology, comorbidity, segregation of service systems, escalation pathways, governance and workforce competencies, are also applicable to developing integrated care responses for gambling disorders. This is an important area for the Commission's attention, especially as up to three quarters of people seeking treatment for gambling disorders have comorbid mental health disorders. Similarly, in a recent large study we conducted on behalf of the Victorian Responsible Gambling Foundation, consumers attending Victorian mental health services were found to be eight times more likely to meet criteria for a gambling disorder than the general population. Mental health clinicians were found to have low levels of confidence in responding to gambling disorder, with less than 15% having received relevant training.¹

¹ Lubman DI, Manning V, Dowling N, Rodda S, Lee S, Garde E, Merkouris S & Volberg R (2017). Problem gambling in people seeking treatment for mental illness. Victorian Responsible Gambling Foundation, Melbourne.

Best practice

- 19 Best practice for the treatment of substance use disorders starts with the recognition that they are legitimate mental health disorders. Like other mental health disorders, they commonly co-occur with other mental health conditions, such as depression, anxiety, psychosis and personality disorders. Co-occurrence of mental health disorders is the norm within treatment settings and the population more broadly, and needs to be recognised as such. Indeed, local and international research clearly demonstrates that the majority of people presenting to alcohol and other drug (**AOD**) treatment services have additional co-occurring mental health disorders, and vice versa.
- 20 When we consider the evidence for what treatment should be offered as best practice, the default should clearly be evidence-based, holistic, person-centred care, delivered by a workforce with relevant competencies. People should expect to receive treatment that reflects their needs, rather than conceptualising them as an assortment of conditions that need to be compartmentalised and referred off to multiple providers for treatment.
- 21 As substance use disorders will commonly co-occur with other mental health disorders, people within the mental health system require appropriate training, support and supervision to treat them in accordance with best practice. Like other mental health disorders, the treatment of substance use disorders requires appropriate resourcing. To ensure that holistic care is provided across service settings, it is critical that the commissioning of health services takes an integrated approach in terms of policy, funding and oversight. The segregation of policy and commissioning for mental health and substance use disorders within the Victorian Department of Health and Human Services (**DHHS**) exacerbates challenges experienced at the service and consumer level in terms of integration. A downstream effect of the segregation and siloing at the policy and commissioning level is the experience of consumers and families in being 'bounced' between services and sectors, as well as limited oversight of client and family outcomes, critical incidents and quality and safety indicators for Victorians presenting to AOD services. For this reason, it is my belief that there should be a single government department with oversight of both the mental health and AOD service systems, as well as their performance, safety and quality.
- 22 However, it is important to state that the two sectors should remain separate at a sector and service level, given differences in treatment philosophies, workforce practices and service offerings. Ideally, each sector should report to a separate division within a single DHHS department, with oversight from a Director responsible for the performance of both sectors, as well as the delivery of integrated care. The opportunity to share knowledge and skills, without either sector overwhelming and consuming the other, should be a guiding principle for structural design. Experiences in amalgamating sectors into one service system interstate has identified that the much larger mental health system tends

to subsume the AOD sector. This includes diversion of funding or key positions, as well as implementing processes, philosophies and systems that are specifically tailored to the management of severe mental illness as opposed to best practice for the management of substance use disorders. New South Wales and Queensland are good recent examples of the challenges experienced and lessons learnt in bringing together the mental health and AOD sectors under one government department.

23 At Turning Point, we operate a broad range of clinical services across the Eastern Health catchment as well as specialist services based in Richmond. A small number of psychiatric and medical registrars, as well as hospital medical officers (**HMOs**), rotate through our clinical program, which is not the norm for the AOD sector more broadly, as medical specialists are not a funded stream of activity in the Victorian AOD service system. Our experience is that many of the trainee doctors and nurses who start working with us are apprehensive about interacting with patients with substance use disorders, which is consistent with community perceptions that people with substance use disorders are dangerous, untrustworthy and unpredictable. It also reflects the limited exposure to addiction curricula and clinical placements that medical and nursing graduates receive as part of their training.

24 It is important to note that by the end of their rotation, the attitudes and skills of these doctors and nurses' in dealing with substance use disorders have dramatically shifted, with many trainees expressing that they found it one of their most fulfilling and exciting rotations. In my opinion, it is a tragedy that most of the healthcare sector, including the majority of doctors and nurses, have not had the opportunity to undertake any formal training within addiction settings and services and this partly explains the poor knowledge, skills and attitudes that the majority of the health workforce hold in relation to people with substance use disorders.

The need for training and structural reform

25 I trained in the United Kingdom as a psychiatrist and addiction specialist, but when I arrived in Victoria in 1999, I was informed that substance use disorders were not treated as part of the mental health system. As such, I was unable to obtain employment in an addiction training post anywhere in Victoria, including within AOD services, as these positions did not exist. Victoria, at that time, did not offer a formal training program for addiction medicine or psychiatry, or fund addiction specialists within a tertiary clinical stream.

26 Even today, addiction medicine and psychiatry are still not a formal part of the health care system in Victoria. This absence of a clinical tertiary addiction stream across the Victorian hospital and health care system has its origins in the period post-deinstitutionalisation. In the asylum era, all mental health disorders were treated within large psychiatric hospitals,

with addiction services a core component of the treatment available. This integration of mental health and addiction services meant that all health practitioners in training (doctors, nurses and allied health staff) would have the opportunity to work within addiction settings as part of their rotation through psychiatric institutions. After deinstitutionalisation, mental health was separated into tertiary clinical services delivered through hospitals, with rehabilitation and recovery services delivered by non-governmental organisations. This structure still allowed health practitioners in training to have real world experiences of working within mental health across hospital and community settings and to receive relevant training. In contrast, after deinstitutionalisation only community-based addiction detox and rehabilitation, counselling and recovery services delivered by non-governmental organisations were funded, with the clinical tertiary arm of addiction services abandoned. This means that for over two decades, medical, nursing and allied health professionals have not had the opportunity to work within addiction settings, and as such, have not gained the requisite knowledge, skills and experience of working with people with substance use disorders, including confidence in the delivery of opiate substitution treatment. This explains the significant stigma and discrimination that is palpable across Victorian health settings towards this population, and the limited number of health professionals, including GPs and mental health practitioners, who offer services to this population. This failure to train an entire generation of health professionals is a significant travesty for Victorians who now present to health care settings with substance use disorders, including those with co-occurring mental illness, and this situation is only going to worsen as the remaining cohort of those who trained in the asylum era retire.

- 27 This structural flaw in the design of the mental health and AOD service system post-deinstitutionalisation has resulted in significant system gaps in relation to clinical tertiary addiction service provision. Tertiary addiction services, supported by addiction medical specialists, have not been provided or funded within the acute care system in Victoria in any systematic way since deinstitutionalisation. This contrasts with service delivery models in other jurisdictions such as New South Wales, which has over 40 funded addiction medical specialist positions within its tertiary addiction stream across the public health system. Since the 1990s across Victoria, there has been a generation of medical, nursing and allied health practitioners who have not had the opportunity to train in addiction settings or interact with Victorians in recovery, and as such, do not have the skills or knowledge to provide evidence-based care to this population, irrespective of setting. This gap in knowledge and experience has led to health practitioners having little confidence in AOD interventions or the treatment system and being pessimistic, even nihilistic, in their views around treatment and recovery. Today, there are limited opportunities across Victoria that allow medical, nursing and allied health practitioners to rotate through addiction services, and to have the opportunity to hear from those with lived experience of what works and what doesn't — even for GPs and mental health

practitioners — despite frequent requests to training bodies for training placements. As a result, there is a fundamental failure in translating evidence around the treatment of substance use disorders into practice across the Victorian health system, contributing to the poor health outcomes that we see for this population, and the limited number of medical practitioners willing to offer evidence-based interventions, including opiate substitution treatment.

- 28 When addressing deficits in skills and knowledge in relation to the treatment of substance use disorders, especially in the context of other co-occurring mental disorders, the Victorian approach has largely consisted of offering large scale brief didactic training workshops. We know from our research, as well as our experience as one of the leading providers of workforce training in addiction, that this approach does not lead to lasting skill development or practice change.² It is also at odds with how competency training is delivered across other health areas, where opportunities to practice and implement what has been taught under accredited supervision is the gold standard. By design, available training is largely geared towards providing screening and brief intervention, which leaves an enormous skill and knowledge gap in how to support people with more severe substance use disorders, including the delivery of evidence-based pharmacotherapies. Given that many of the same aetiological factors (such as trauma and loss) underpin the development of distinct mental health disorders, including substance use disorders, there is a need to build clinical skills in evidence-based interventions and models of care that address these conditions in an integrated manner.
- 29 This will require resourcing of a specialist tertiary addiction stream across both the public mental health and AOD sectors, to ensure an escalation pathway of primary and secondary consultation, accredited placements and supervision. A tertiary addiction stream would also be able to in-reach into Victorian hospitals to provide addiction consultation liaison services that support emergency departments and the acute hospital system. This is critically important given evidence by Professor Diana Egerton-Warburton and others, that up to a third of emergency department patients have alcohol-related presentations, while the majority of Victorians undergoing alcohol and drug withdrawal do so in acute hospital beds.³ These gaps in health knowledge and service delivery explain the high (and growing) rates of morbidity and mortality among people with substance use disorders, including rising opioid deaths and suicide, and the limited availability of opiate substitution treatment programs across Victorian health care settings. In fact, despite

² Hall K, Staiger PK, Simpson A, Best D & Lubman DI (2016). After 30 years of dissemination, have we achieved sustained practice change in motivational interviewing? *Addiction*; 111: 1144–1150

³ Egerton-Warburton D, Gosbell A, Wadsworth A, Fatovich DM & Richardson DB (2014). Survey of alcohol-related presentations to Australasian emergency departments. *Medical Journal of Australia*; 201: 584-587.

being one of the highest risk groups of people to die by suicide, suicide prevention policies and strategies typically fail to deliver and fund interventions to people who present with substance use disorders, with limited mental health and suicide prevention capacity within Victorian AOD services.

Question 2. A significant number of stakeholders have called for greater ‘integrated care’ for people with co-occurring mental illness and problematic alcohol and other drug use:

a. how do you define ‘integrated care’?

30 Integrated care refers to an inclusive, person-centred approach that addresses an individual’s needs in a holistic manner for the entirety of their treatment journey. It requires services to be collaborative and needs-led, and not constrained by administrative or organisational practices. At its most basic, integrated care means that a person’s mental illness and substance use disorder are treated simultaneously.

31 Unfortunately, the current scenario in Victoria is typically one of serial (one disorder treated at a time) or parallel (at the same time by different services) care. It is predicated on the notion that the two disorders can be treated separately as distinct disorders, despite clear evidence that they are inter-related. It is akin to treating depression in one service and asking the individual to go and seek treatment elsewhere for their anxiety. This situation reflects the impact of continued siloing of the mental health and AOD sectors, as well as the training and skill gaps of the respective workforces. Unfortunately, a tragic consequence of this approach is that many consumers with co-occurring disorders are bounced between services or excluded from them, and are unable to access appropriate addiction psychiatry support.

32 The poor outcomes associated with this population can lead to the perception that treatment is ineffective or that consumers are responsible (they ‘failed treatment’), when in reality they received disparate and disjointed care that failed to adequately address their individual needs. Such practices persist despite clear evidence that serial and parallel approaches typically result in poor health and social outcomes, while the best outcomes are achieved when co-occurring disorders are treated simultaneously by a skilled and capable workforce.

b. what are the ways this can be achieved?

33 In its simplest form, integrated care can be achieved through AOD and mental health services working together in partnership, with clear shared treatment goals and practices,

such as information sharing, joint care planning and supervision.⁴ Ideally, integrated care should be provided in a single service setting to minimise any additional barriers to care, as this population typically find it challenging to present to multiple services, and are more likely to drop out of treatment or present in crisis.

- 34 This could be achieved through co-location of services, or the embedding of addiction clinicians within a mental health service or vice versa, to ensure that a person receives the highest quality care wherever they present — a ‘no wrong door’. In terms of the latter model, this could be delivered through inter-agency agreements and partnerships, or by directly employing dual trained clinicians to work within a particular service. While directly employing a dual trained clinician may seem a relatively straightforward approach, there needs to be clear models of care, supervision structures and supports in place to make sure that the identified clinician is not isolated, overwhelmed, deskilled or absorbed into the general workforce. There also needs to be a mechanism to ensure appropriate escalation pathways with ready access to tertiary addiction specialist support.
- 35 It is important to note that while policies related to providing integrated care are typically targeted at services or clinicians, our research around delivering effective integrated care highlights the need for interconnected strategies that span commissioning, organisational priorities, service delivery models and clinical practices. This includes ensuring that integrated care is incorporated within service specifications of commissioning bodies and is adequately funded, organisations have a shared sense of purpose and priorities and that there are sustained coaching activities within services focussed on implementation of integrated care and capacity building.
- 36 We also need to put peers at the heart of this reform, to show us what integrated care looks like, what we are aiming for and what can be achieved. This includes hearing more of the success stories, particularly within training programs and across services, to build a culture of hope and expectation. Indeed, work that we conducted as part of Patient Pathways, one of Australia’s largest treatment outcome studies, demonstrated the critical importance of peer support in enhancing treatment effectiveness among people with substance use disorders.⁵ As such, the inclusion of peer support as a key component of integrated care ensures examples of success are readily available to consumers and families, resulting in increased engagement and participation in treatment, as well as improved connection to recovery supports within the community.

⁴ Savic M, Best D, Manning V & Lubman DI (2017). Strategies to facilitate integrated care for people with alcohol and drug problems: a systematic review. *Substance Abuse Treatment, Prevention & Policy*, 12: 19.

⁵ Manning V, Garfield JB, Best D, Berends L, Room R, Mugavin J, Larner A, Lam T, Buykx P, Allsop S & Lubman DI (2017). Substance use outcomes following treatment: findings from the Australian Patient Pathways Study. *Australian & New Zealand Journal of Psychiatry*, 51: 177-189.

Question 3. In a future redesigned system, what would be the specific components, structures or processes that would need to be in place to enable an experience of integrated care for people living with both mental illness and problematic alcohol and other drug use from the consumer perspective?

- 37 The experience from a consumer perspective would be one of seamless, holistic treatment with a single team of clinicians providing wraparound care, including early access to peer support. However, the components, structures and processes would need to be informed by the level of severity of the distinct disorders.
- 38 A critical component of a new redesigned system is the creation of a clinical tertiary addiction service stream that has been absent since deinstitutionalisation, comprising senior dual trained mental health professionals (including nurses and allied health), addiction medical specialists, addiction psychiatrists and experienced peer navigators. I anticipate that an investment of \$30 million per annum to create a tertiary addiction service stream could deliver the necessary structural transformation that would be a key impetus for providing high quality integrated care across Victoria. With a tertiary addiction stream in place, Victoria would be in a prime position to provide specialist in-reach into both the existing mental health and AOD systems, offering escalation pathways for primary and secondary consultation, opiate substitution treatment, specialist interventions, supervision, training, policy development and clinical placements. It would also support GPs' confidence and skills in managing substance use disorders, through a specialist consultation model that is similar to how other medical fields operate, including general medicine and psychiatry. The creation of a tertiary specialist stream would facilitate rapid access to key knowledge and skills across the health system, and address key gaps in current service delivery. For example, AOD agencies are frequently unable to access mental health/psychiatry assessment from local mental health providers due to demand pressures or the requirement that treatment can only be offered when the substance use disorder has resolved, while mental health services are unable to access addiction specialist assessments, support or supervision.
- 39 With support of a tertiary addiction service stream, the AOD system could manage most consumers with mild-moderate and stable severe mental illness with co-occurring severe substance use disorders. This would ensure that the majority of these consumers could be effectively treated outside the public mental health system, with clear escalation pathways also available. The fact that private addiction and psychiatry clinics are limited in their ability to manage this cohort, due to consumers' limited ability to pay private fees, highlights the importance of providing adequate mental health capacity within the AOD system.
- 40 In terms of the mental health system, most clinicians should be able to manage mild-severe substance use disorders with appropriate training, supervision and support

from a tertiary addiction service stream. However, there is an urgent need to create a new service model for consumers with complex needs (typically involving co-occurring severe substance use disorders), as neither system is currently capable of offering effective treatment to this group within existing resources and models of care. Ideally, this integrated service model would incorporate tertiary specialist expertise from both the addiction and mental health sectors working within one team and one philosophy, spanning both outpatient and inpatient care, with access to community housing, employment support, peer support and integrated long-stay residential rehabilitation. An assertive community treatment (**ACT**) model should be considered given its strong evidence base for this population.

Question 4. What else should be in place for a future system to deliver more integrated care to people living with both mental illness and problematic alcohol and other drug use, including from the perspective of governance, operations or funding?

- 41 At Turning Point, we have developed and tested models of integrated care for consumers with complex needs, and share these insights with colleagues across the mental health sector. However, we are currently not funded for this activity and are often dissuaded by structural impediments in pursuing this work. It should be easier, not harder, to provide integrated care for a person in need.
- 42 Implementing effective integrated care necessitates system investment, inter-departmental collaboration and clear service specifications. If DHHS is to maintain separate departments to oversee the mental health and AOD systems, then it is critical there are clear processes in place to ensure joint planning, funding and performance monitoring. However, given that substance use disorders are indeed mental disorders and there are high rates of comorbidity across sectors, it is important that the Royal Commission consider incorporating oversight of both service systems within one department, to ensure integration at the highest level. This is likely to dramatically improve system planning, performance and improvement activities related to integrated care, as well as workforce planning and capacity building. A joint department would also address a major risk for the Victorian government related to the AOD system in terms of consumer safety and quality, with no current oversight or departmental review processes in place for sentinel events, emerging safety issues, clinical excellence or health care improvement.
- 43 A lack of oversight of critical incidents and safety and quality issues across the AOD system is a serious concern in relation to protecting the Victorian community, particularly as substance use disorders are major contributors to deaths, sentinel events and occupational health incidents. In fact, alcohol alone is the sixth highest risk factor for burden of disease in Australia, contributing to more than 70,000 hospital presentations each year, while opioid-related deaths have almost doubled over the past decade. This

lack of system oversight is in stark contrast to the significant work conducted by the Chief Psychiatrist's office within the mental health branch of DHHS, as well as that of Safer Care Victoria for health more broadly. It is my opinion that there is an urgent need to establish clinical governance oversight of the AOD system within DHHS, to ensure that integrated care is delivered according to best practice, and without unintended harm, with robust mechanisms in place to improve the overall quality and safety of the system. This should include review of deaths, critical incidents, complaints and patient outcomes, with a focus on quality of life and the effectiveness of treatment. It should also include oversight of community prescribing practices related to complex pharmaceutical opioid and other drug dependence, given the increasing number of drug-related deaths and suicides associated with these medications in Victoria. This is an area of critical need, especially given Victoria's recent roll-out of its real time prescription monitoring system, SafeScript.

- 44 Effective treatment of substance use disorders is underpinned by a robust quality framework. Turning Point was commissioned to deliver a draft national quality framework for the federal government, and there are opportunities to build on this work so that Victoria can be leaders in delivering high quality integrated services. Without a clear set of national standards, anyone can open an AOD service in Victoria without specialised qualifications or evidence-based models of care. This puts consumers and families at risk of exploitation. Victoria needs to ensure that there is a robust quality framework for AOD services, supported by a highly skilled and capable workforce, with services appropriately resourced to deliver quality, planning and innovation activities.
- 45 Currently, the minimum qualification for delivering AOD treatment in Victoria is a Certificate IV in Alcohol and Other Drugs, meaning that clinicians have limited experience or expertise in managing co-occurring mental illness. A lack of skills and experience necessary to appropriately assess and manage co-occurring mental illness within the AOD sector has been identified as a key barrier to effective service provision, and building workforce capabilities has been identified as a priority for the Victorian Government. Funding to boost the capacity of the AOD workforce to respond to mental illness and providing suicide prevention initiatives within these services must be key priorities in ensuring the delivery of integrated care, reducing the risk of suicide among this population of Victorians, as well as easing the demand on public mental health services.

Question 5. Are different service responses required depending on the severity and complexity of the clients support needs? If so, how do you 'stream' clients for these responses?

- 46 It is critical that the health system is able to tailor service response to client need, akin to a stepped care model. For other health conditions, such as diabetes, heart disease and cancer, there has been considerable work undertaken to develop clear models of care

that provide consensus in terms of service responses and escalation pathways depending on the severity and complexity of the presentation. They also provide clarity in terms of who is responsible for delivering each aspect of care, from primary care through to tertiary services. Such models ensure that Australians can be confident that wherever they live, they will receive a consistent treatment response.

- 47 In 2017, Turning Point was commissioned by DHHS to conduct a review of AOD service planning across the state.⁶ As part of the review, the Victorian treatment-seeking population was segmented into tiers, in order to create a population planning tool that matched consumers with differing levels of addiction severity and complexity to 'packages' of care. Within each tier, the presence of complexity factors, which included comorbid mental illness, was critical in determining the level of care a consumer needed to receive. Tiered models can be invaluable for system planning, and also provide the opportunity to conduct cost benefit analyses. They allow the system to be able to plan for the level of intervention and workforce competency needed, based on the severity and complexity of presentations, thereby informing prevention, primary care, mental health and AOD service activities.
- 48 To deliver a system of effective streaming based on consumer need, a clear model of integrated care must be developed for each tier based on:
- (a) the level of severity and complexity of presentation;
 - (b) what the evidence supports as effective treatment;
 - (c) workforce competencies related to the intervention to be offered;
 - (d) criteria for stepping care 'up' or 'down'; and
 - (e) clear escalation pathways if treatment is not working for that individual.

Other service models

- 49 A fundamental challenge in ensuring the delivery of an appropriate integrated care service response is the nature by which services are currently commissioned. Unlike other areas of health, there has been limited investment within the AOD system in terms of demand modelling, quality frameworks, clinical model development, escalation pathways and workforce competencies, despite consumers presenting with significant mental health comorbidities. This is in part due to the segregation of the AOD sector from mainstream health care, a prevailing belief that addiction is not treatable, and the absence of a strong lived experience platform for consumers and carers. Without an agreed model of integrated care and associated workforce capability and resourcing, there is a lack of

⁶ Lubman DI, Manning V & Cheetham A (2017). Informing alcohol and drug service planning in Victoria. Fitzroy: Turning Point.

clarity in terms of what is offered to consumers, and when to escalate treatment to a higher level of care or service.

- 50 A key issue with the current AOD system is the absence of escalation pathways, and the lack of a tertiary addiction specialist stream, as in other states. For example, New South Wales has a dedicated and large tertiary addiction specialist stream within hospital networks that in-reaches into the emergency department, hospital, primary care, mental health and AOD systems. New South Wales also has a clear model of how the AOD sector operates as a system. In Victoria, the AOD system is not currently configured to work as a system (unlike the mental health service sector), with care largely provided within single agencies or consortia in a flat, unidimensional structure. This means that for most consumers who do not respond to standard care, there is limited capacity or systems in place to escalate (or stream) treatment to a higher tier of evidence-based interventions or service responses.

Question 6. What are the knowledge, skills and attitudes needed in a complexity capable workforce providing holistic, person-centred support?

- 51 To be able to support consumers with holistic, person-centred support, a critical first step is the development of clear models of care and workforce competencies that articulate what is expected to be delivered when and by whom. This includes the specific evidence-based interventions to be offered and related workforce competencies at every stage, with clear escalation pathways describing the next stage of intervention and related competencies. Workforce training must also include peer role models who can speak to the benefit of the care they received. Currently, there are no clear models of integrated care within the Victorian health system, and as such, limited guidance on the knowledge, skills and attitudes needed in a complexity capable workforce.
- 52 Basic competencies should be framed around essential knowledge and core practice skills. This should include an understanding of the nature of comorbidity, its aetiology, interactions and impact, and models of intervention and recovery, as well as the ability to engage and respond in a non-judgmental and compassionate manner with interventions that can be matched to the person's level of need. Higher level competencies build on these elements and are targeted to more highly skilled workforces that are able to support the broader workforce, offering referral pathways for those individuals who require escalation in their level of intervention and support. This must include upskilling of the medical workforce to be able to provide evidence-based pharmacotherapies, including the delivery of opiate substitution treatment within mental health settings.
- 53 These competencies should be underpinned by a set of shared principles and values, including respect, responsiveness, recovery, collaboration, inclusion and excellence, as articulated by previous work in this area.

- 54 There has been significant work conducted in terms of workforce competencies, including a capability checklist developed in Victoria in 2009 by Gary Croton, as well as other excellent frameworks developed in Tasmania, New South Wales and New Zealand.⁷
- 55 The evidence is clear however, that knowledge, skills and attitudes alone do not lead to a change in work practice without clear organisational and workforce support. Our work and others has shown that integrated practices are only sustainable when there are clear pathways for primary and secondary consultation, supervision and joint care planning, as well as common organisational goals and positive inter-agency relationships.

Question 7: What are the opportunities for joint mental health and alcohol and other drug workforce training and development?

a. Are there examples of where this is being done successfully?

- 56 The Sax Institute, on behalf of the New South Wales Mental Health and Drug and Alcohol Office, published a report in 2014 that explored existing models of care, their efficacy and key considerations and recommendations in the design of best practice models.⁸ I would like to draw the Commission's attention to this report as I feel it provides an important review of the evidence that can inform the development of a Victorian framework of integrated care.
- 57 The most successful and effective examples of truly integrated care, both here and overseas, have clearly articulated models of care with dedicated staffing with defined skills and competencies. However, these services have generally not been replicated across the service system, due to the segregation and siloing of the mental health and AOD sectors, and the inherent bureaucratic challenges in commissioning integrated service models.

⁷ Croton G. (2009) Dual Diagnosis Capability Checklist: Alcohol, Tobacco and Other Drug Workers North East Health, Wangaratta. Available online at: http://www.dualdiagnosis.org.au/home/index.php?option=com_docman&task=cat_view&gid=39&Itemid=27

Croton G. (2009) Dual Diagnosis Capability Checklist: Agency or Service Level (Non-Victorian) North East Health, Wangaratta. Available online at: http://www.dualdiagnosis.org.au/home/index.php?option=com_docman&task=cat_view&gid=39&Itemid=27

NZ Ministry of Health (2008). Let's Get Real: Real Skills for People Working in Mental Health and Addiction. Ministry of Health: Wellington, NZ.

⁸ Deady M, Barrett EL, Mills KL, Kay-Lambkin F, Haber P, Shand F, Baker A, Baillie A, Christensen H, Manns L, Teesson M. Effective models of care for comorbid mental illness and illicit substance use: An Evidence Check review brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Mental Health and Drug and Alcohol Office.

b. *How do you implement joint training approaches at scale?*

58 Implementation of the training required to ensure the delivery of integrated care is achievable with sufficient resourcing and a phased plan of activity. The Royal Commission should look to the delivery of new training and programs delivered through the Victorian family violence reforms to gain greater insight into what has and has not worked in terms of large-scale implementation.

59 The first step in developing appropriate training is to identify the key competencies that are required of particular workforces to be able to deliver a comprehensive model of evidence-based integrated care for Victoria. This would inform the development of a training framework that is able to deliver and ensure key competencies are obtained. Developing key competencies will undoubtedly require accredited training rotations and placements that allow for hands on experience in delivering key aspects of integrated care under appropriate supervision.

60 To ensure these competencies remain achievable over the long term, assessment and treatment of substance use disorders needs to be embedded as a core competency in undergraduate and postgraduate teaching at all levels of health practitioner training, with opportunities for hands-on training placements within AOD settings. However, this is harder than it sounds, as there are few clinical academics with expertise in addiction that can provide the teaching and training necessary within Victorian universities. This is a consequence of a lack of investment in tertiary addiction services in Victoria since deinstitutionalisation, as well as limited funding of clinical addiction academic positions. Sadly, I am the only full professor of addiction in Victoria with a medical background, and one of the only professors of addiction psychiatry in the whole of Australia. In contrast, New South Wales has more than five clinical professors of addiction medicine, while most other medical specialities in Victoria, such as oncology, gastroenterology, haematology and psychiatry, have many more. Unfortunately, the dearth of addiction academic positions is also true for nursing, psychology and social work.

61 This deficit in clinical addiction academic positions across health disciplines means that there is limited addiction input into university health curricula and limited capacity to educate the next generation of health professionals. While AOD education was implemented across medical schools in Australia in the 1990s with funding from the Commonwealth, after this funding ceased universities did not have the resources to continue offering this material in depth. This helps explain why the Victorian health workforce has such limited capacity to respond to substance use disorders in an evidence-based manner. This critical gap in clinical addiction academic funding is underpinned by the failure to recognise addiction medicine and psychiatry as core medical specialties within the Victorian public health system and to adequately fund addiction medical training and consultant positions.

- 62 Given the prevalence of alcohol and drug-related presentations within ambulance, primary and acute care, as well as across the mental health system, it is critical that addiction training is considered a core competency within medical, nursing and allied health undergraduate and postgraduate training. In an attempt to address this skills deficit in postgraduate training, Turning Point has developed a Graduate Certificate and Masters program in Addictive Behaviours in collaboration with Monash University, which includes core units on addiction assessment and treatment, as well as specific units on co-occurring disorders and recovery principles. Importantly, DHHS offers a small number of scholarships to complete the Graduate Certificate, but Turning Point is typically inundated with applications, highlighting the enormous thirst for knowledge in this area among health professionals.
- 63 Turning Point is regularly contacted by GP trainees and general practitioners from across Victoria, who recognise that they need to develop their competencies in managing substance use disorders, as they received limited training in addiction during their undergraduate and postgraduate training. They report that this has limited their ability to manage substance use disorders within primary care, despite its high prevalence. Unfortunately, there is no dedicated funding available to offer addiction training placements to GP trainees in Victoria, outside of MBS rebates, which further limits the ability of primary care to deliver integrated care in an ongoing fashion, in direct contrast to other chronic health disorders. Funding should be established to ensure Victorian GPs are able to gain the requisite skills they need to deliver best practice care, through supported placements in accredited AOD settings. Limited funding for addiction medical specialist positions within the Victorian public health system further exacerbates these skill gaps, as GPs are also unable to receive the necessary specialist advice and support they need to care for their patients, exacerbating the poor treatment outcomes for this population.

Question 8. What new roles, training and development are needed for mental health and alcohol and other drug workforces to enable integrated practice?

- 64 Given the common co-occurrence of mental health and substance use disorders, integrated practice should be considered standard practice, and should be a basic competency for all clinicians working across the mental health and AOD sectors.
- 65 This will require the development of a core competency course that draws on the expertise of existing training organisations within the Victorian mental health and AOD sectors, including the voice of consumers and families. Peer involvement is core to this training, offering visible reminders that treatment can work. Indeed, unlike most other health conditions, the stigma around substance use disorders means that health practitioners rarely hear common stories of success.

- 66 A comprehensive curriculum will need to be developed, and clinicians will need to receive ongoing coaching, mentoring and clinical supervision from accredited trainers to ensure implementation of skills and knowledge into the workplace. Clinical rotations to accredited training posts across agencies are also likely to be of benefit.
- 67 Activities that have been found to be valuable in supporting clinicians to deliver new models of practice include the opportunity for specialist consultation, supervision and case reviews, facilitating inter-agency partnerships and ensuring organisational support to assist with the adoption of new processes and policies. Indeed, the effectiveness of delivering these activities is highly influenced by the prevailing organisational culture. Workforce development approaches should therefore have a 'systems focus' that targets organisational and structural factors in addition to addressing the education and training of individual workers.
- 68 There will also need to be greater support of postgraduate addiction training opportunities for psychiatry, psychology, social work and mental health nursing within the AOD sector. Effective capacity building will also require the recruitment of clinicians experienced in managing co-occurring disorders, who can assist in training and service development. There will also be opportunities to draw on existing higher education courses that have an addiction focus.

TURNING POINT

- 69 Turning Point is Australia's leading national addiction treatment, research and training centre. Turning Point is part of Eastern Health and is affiliated with Monash University. Turning Point provides clinical care across the eastern metropolitan region as part of the Eastern Consortium of Alcohol and Drug Services, specialist addiction services in Richmond, and over 20 telephone and online helpline services across multiple jurisdictions as well as nationally. Turning Point conducts research on behalf of the state and federal government, as well as local and national funding bodies. Turning Point offers accredited training courses, workforce development and leadership programs, as well as a Masters program in partnership with Monash University.

a. *The Eastern Consortium of Alcohol and Drug Services*

- 70 Turning Point is the lead agency for the two consortia of alcohol and drug service providers across the Eastern metropolitan region of Melbourne, who have formed a partnership under the banner of the Eastern Consortium of Alcohol and Drug Services (**ECADS**). ECADS delivers services in the Inner East of Melbourne, which includes the Local Government Areas of Boroondara, Manningham, Whitehorse and Monash, as well as Eastern Melbourne, which includes the Local Government Areas of Knox, Maroondah and Yarra Ranges.

b. *Services provided*

71 Turning Point is responsible for coordinating the services provided by the consortium, and provides intake, assessment, counselling, care and recovery, and withdrawal services. Turning Point also offers a specialist pharmacotherapy service that provides opiate substitution treatment to patients with complex needs, addiction psychiatry specialist assessments, as well as an addiction consultation liaison service to Eastern Health hospital sites. Turning Point operates the Addiction Medicine Unit at Box Hill Hospital and Wellington House, which offers a subacute withdrawal and stabilisation service. Turning Point employs a full suite of health professionals, including addiction medical specialists and trainees, as well as a peer workforce.

c. *Access to services*

72 A consumer can access services at ECADS by ringing the central intake number and making an appointment, or through referral by their GP. Turning Point also offers a 'walk in' service at Box Hill. No appointment is needed.

d. *Limitations*

73 The limitations of ECADS are a result of how the broader AOD system is configured and resourced. Essentially, the AOD system is only funded to provide brief episodes of treatment rather than continuing care, with no identified pathways for escalation, meaning that the sector is inadequately prepared to meet the complex needs of many Victorians who present for treatment. For example, AOD services are only funded to treat people with substance use disorders for up to twelve sessions, which is an appropriate model for those with mild to moderate illness. However, due to extended delays in help-seeking, we typically do not see people until they have developed a severe illness with multiple complications. There are limited resources available to treat individuals at the severe end of the spectrum and a lack of escalation pathways to more specialist support.

74 The enormous stigma and discrimination which exists in relation to substance use disorders results in substantial delays in help-seeking. Research consistently identifies that on average, a person will wait 18 years from when they develop a substance use disorder until they seek professional help. This is an absolute tragedy, especially given the enormous investment seen in other areas of health in terms of promoting early intervention. By the time the person presents for treatment, they will generally have developed a range of complications, including poor physical and mental health, collateral trauma, social disruption, family breakdown, housing instability and potentially criminal justice involvement.

75 The AOD sector is only funded to treat the substance use disorder in isolation, the polar opposite of integrated care, and not any associated physical or mental health disorders,

or related social problems, including the impact on families. This is at odds with the treatment for other chronic health conditions. It is akin to only providing treatment related to glycaemic control in diabetes, and neglecting the associated cardiac, kidney, skin and vascular disease. This is particularly problematic given the discrimination frequently experienced by Victorians with substance use disorders within primary care, acute care and mental health services, when they seek assistance for their physical or mental health conditions. They are also likely to be told by mental health services that they need to be in full recovery from their substance use disorder before they can obtain treatment for any comorbid mental health disorders. This is not evidence-based clinical practice, but service delivery through the lens of a siloed system, where health practitioners do not feel appropriately skilled or obligated to manage presentations where substance use disorders are comorbid. It is a travesty that cannot continue.

- 76 Indeed, there are many primary care settings across Victoria that refuse to treat consumers with alcohol and drug use disorders, even if they present with mental illness, as they see this group as too difficult or complex to manage. The exclusion of Victorians with genuine health conditions from our primary care system is unconscionable, and needs to be addressed at the highest level, to ensure that discrimination of Victorians with mental health disorders is prohibited and optimal care is promoted.
- 77 At Turning Point, we are inundated with referrals from AOD services, GPs and mental health providers to deliver specialist addiction psychiatry assessment and treatment of Victorians with comorbid mental illness and substance use disorders. We are only funded to provide a small service and cannot meet the overwhelming demand for integrated medical and psychosocial care. This is due to skill deficits in the current psychiatry and mental health workforce, as well as primary care. AOD services themselves are not able to access public mental health or private psychiatry or psychology support for their client group, due to limited addiction psychiatry expertise in these settings, meaning that many vulnerable Victorians miss out and their recovery is delayed. Funding for a tertiary addiction service stream across Victoria is key, as this would provide capacity to provide addiction psychiatry in-reach into AOD and mental health services, as well as building GP confidence and competency.
- 78 I would also like to highlight the significant gap in funding that the sector experiences in terms of supporting families and offering peer support. Unlike the mental health sector, there is virtually no funding to deliver evidence-based family interventions with appropriately trained staff, despite their efficacy. Similarly, the sector is unable to embed peer support and lived experience within our treatment model, despite recognition of its prime importance in supporting recovery. This is in contrast to the mental health sector, where funded peer support roles are identified as best practice and are deemed core to the recovery model.

CO-OCCURRING SUBSTANCE USE DISORDERS AND OTHER MENTAL ILLNESS

The relationship and interplay between mental health and substance use disorders

a. *The impact of substance use disorders on mental health problems*

79 Early-onset, or regular substance use during adolescence, increases the risk of developing mental health disorders during late adolescence and early adulthood, as well as a range of other adverse outcomes that may increase the risk of mental ill-health, including educational underachievement, health problems as a result of accidents and injuries, and social difficulties.

80 People of all ages use substances to alter their brain chemistry and mental state. It is therefore not surprising that long-term use of most psychoactive drugs, including alcohol, is associated with the development of mental health symptoms and disorders. For example, long-term alcohol use can lead to depression, anxiety and even psychosis, while even short-term methamphetamine use can trigger depression, anxiety and psychosis.

81 It is important to note that some mental health syndromes are a consequence of altered brain chemistry induced by drug use, and may resolve when the person stops using drugs, whereas for others, the disorders persist even when the substance use stops. For example, psychosis induced by methamphetamine or cannabis may resolve when the drug use stops, however for some people, the drugs may have triggered an underlying psychosis that persists. This highlights the challenges in assessing and treating Victorians with comorbid disorders, and the importance of a workforce who are skilled and are able to match the treatment response to the person's needs. This means not excluding those who present to mental health services with co-occurring mental illness and substance use disorders, and ensuring that any underlying substance use disorder is appropriately treated.

82 In relation to a person who has developed a co-occurring substance use disorder, generally the more comorbidities a person has, the poorer outcomes they will experience overall. Co-occurring substance use disorders have a significant impact on:

- (a) treatment outcomes for other mental health disorders;
- (b) rates of suicide;
- (c) physical health;
- (d) family functioning;
- (e) relapse rates;
- (f) rates of acute service use;

- (g) the likelihood that a person will be non-adherent to their treatment or medication regimen;
- (h) the likelihood that a person will disengage from treatment;
- (i) the likelihood that a person will be homeless and on welfare; and
- (j) the likelihood that a person will be engaged with the criminal justice system.

83 Importantly, Victorian and international evidence demonstrates that co-occurring substance use disorders are one of the biggest predictors of re-admission to inpatient mental health units among people with mental illness, as well as a major driver of morbidity and mortality in the mental health system. For example, research we conducted examining clinical incidents within Eastern Health's mental health program across multiple years, identified that over half of the clinical incidents with an incident severity rating (ISR) of 1 or 2 involved consumers with co-occurring substance use disorders.

84 The risk of suicidal behaviour is also elevated in those diagnosed with substance use disorders. Globally, alcohol and drug use disorders were responsible for almost one-fifth of suicide-related disability-adjusted life years in 2010, with 13.3% of this burden attributable to alcohol use disorders alone, second only to depression. Although research consistently estimates that between one-quarter to one-third of suicide decedents meet diagnostic criteria for alcohol use disorder,⁹ specific suicide prevention strategies targeting individuals with such disorders remain notably absent, with this population infrequently identified as an important 'at risk' group within Victorian suicide prevention strategies and initiatives.

b. Impact of the consumption of alcohol and other drugs on the effectiveness of pharmacotherapy and other mental health treatments

85 The consumption of alcohol and other drugs can affect the effectiveness of a range of pharmaceutical drugs in the treatment of both physical and mental health disorders. In terms of mental health, heavy and regular use of alcohol and drugs as a reflection of an underlying substance use disorder, have been found to affect both medication adherence and effectiveness.

86 However, there is considerable evidence that doctors do not readily identify or treat substance use disorders due to gaps in their knowledge and skills, with many patients also reluctant to discuss their alcohol or drug use due to fears of discrimination. As a result, polypharmacy is common in patients with co-occurring mental illness and substance use disorders, as doctors attempt to address poor treatment responses with

⁹ Witt K & Lubman DI (2018). Effective suicide prevention: Where is the discussion on alcohol? *Australian & New Zealand Journal of Psychiatry*; 52: 507-508.

greater doses or classes of pharmaceutical medications, despite limited evidence to support this approach.

- 87 Indeed, if an individual with co-occurring mental illness and substance use disorders does not respond to medication, it is likely that the mental health condition has been exacerbated by the underlying alcohol and drug use, and alternate evidence-based treatment approaches are indicated. For example, international studies consistently report that many people with alcohol use disorders are treated with antidepressants due to the depressive syndrome they present with. For many people, the alcohol use disorder is not identified nor appropriately managed. Systematic reviews also indicate that it is not possible to determine whether the depression is related to the drinking or independent of this, and have found that the best outcomes occur when antidepressants are commenced following a period of detox, if symptoms persist. This highlights the importance of integrating withdrawal services within a model of best practice mental health care, however currently this is not possible in Victoria due to the siloing of sectors and the limited addiction psychiatry support available within the AOD sector.
- 88 It is also important to note that nearly all of the international published clinical trials of psychiatric medications exclude people with comorbid substance use disorders from participation in their studies. This means that our current evidence base for pharmaceutical drugs is based on mental health populations without one of the most common comorbidities that we see in mental health services. This further discrimination of this population means that we have limited evidence to guide our clinical decision making in terms of pharmacotherapy, and a skill deficit in terms of alternate psychological approaches to managing co-occurring mental illness and substance use disorders within the mental health and AOD sectors.

i. Impact on consumers with severe co-occurring substance use disorders

- 89 The impact is greatest for those with co-occurring severe substance use disorders, as they are typically blamed for their lack of treatment progress, despite the ineffectiveness of current models of care, and are frequently excluded from receiving treatment within mental health settings due to the mistaken belief that their issues can be better managed within AOD services. However, when this population presents to AOD services, the sector is not adequately resourced to provide suitable evidence-based interventions, and have limited access to addiction psychiatry expertise due to the absence of a tertiary clinical addiction stream and limited funded specialist positions across Victoria.

c. *Self-medication by consumers with alcohol and other drugs to manage their mental illness and or the side effects of medication*

- 90 Alcohol and drugs are commonly used by Australians to help cope with stress, anxiety, pain and insomnia. They are also powerful emotional analgesics, and for Victorians who are victims of trauma, are a common way to help them deal with the significant accompanying mental distress. Research exploring self-medication among people with mental illness have identified dysphoria, anxiety and boredom as major drivers of continued alcohol and drug use, as well as helping to cope with emotional and psychosocial problems associated with their illness — for example, family conflict, trauma, financial problems, lack of vocational opportunities and social isolation. Such findings highlight the need for a multifaceted treatment approach in supporting Victorians with co-occurring mental illness and substance use disorders, as many of these underlying drivers will need to be addressed for treatment to be successful.
- 91 The impact is most significant for consumers with severe mental illness, limited financial and social supports, and few other coping skills. Experiences of trauma, family conflict, poverty, homelessness and other social difficulties impact on hope, meaning, identity, empowerment and connectedness, which are at the core of poor recovery outcomes. Given many of these consumers are bounced between services and sectors in the absence of a clearly articulated treatment framework, it is not surprising that they have poor health and social outcomes.

Challenges for people with co-occurring mental illness and substance use disorders

- 92 As discussed earlier, people with co-occurring mental illness and substance use disorder often fall through the gaps in service provision, or are bounced between services and sectors. This is due to a significant gap in workforce competency and capability, the absence of a tertiary addiction specialist stream, and existing models of care that do not include evidence-based approaches to integrated care. As a result, the consumer is typically blamed for 'failing treatment' as the available treatment response is not designed or suited to this population. In turn, this leads to repeated presentations to acute health and emergency services, including ambulances, emergency departments and police, with a revolving door of crisis presentations and short-term care, and a feeling of frustration and nihilism among consumers, families, police and health professionals. Ultimately this population are at high risk of misadventure, including suicide, as evident in the multiple deaths and major incidents investigated by the Victorian Chief Psychiatrist's Office and the Coroners Court of Victoria.

a. *The challenges for mental health services in supporting people with different types of substance use disorders*

93 A major challenge for Victorian mental health services overall is the level of demand on the service system and the available resourcing. The system is overwhelmed, and understandably services are trying to make very difficult decisions about who can be offered support. Given these constraints, the mental health system is focussed on supporting consumers with mental illness who are at serious risk of harm to themselves or others, and as a result need to exclude other consumers who are not deemed to meet these criteria. With limited training in managing substance use disorders available throughout undergraduate and postgraduate training, most mental health staff do not have the necessary competencies to deal with this population and hold similar stigmatising views towards this population as the general public. Without a tertiary specialist addiction stream in Victoria to provide clinical input, supervision, training and support, these skills gaps and discriminatory attitudes remain unchallenged, with limited impetus to change practice given other priorities and demands on the system.

b. *The challenges for alcohol and other drug services in supporting people with different types of mental health problems or illness*

94 A major challenge for AOD services is that many Victorians with co-occurring substance use disorders and mental illness are not eligible to receive psychiatric and case management support from mental health services. This may be because the service views their mental illness as being a result of their substance use and therefore best managed within AOD settings, or their mental illness is not deemed severe enough or risky enough to meet the threshold for receiving mental health service support. The issue here is that this patient group are not catered for by private psychiatry services, due to an inability to afford private fees.

95 At the same time, the mental health system is not aware that the AOD sector does not have the workforce or capacity to manage these patients without specialist mental health input, as they are not funded to offer this level of care, and there is a missing layer of tertiary addiction psychiatry support across Victoria. As a result, the AOD sector needs to support a significant number of Victorians with high levels of psychiatric disability and risk, without the necessary governance, quality framework, workforce competencies, escalation pathways and support systems in place.

96 Further to this, residential AOD services, including both withdrawal and rehabilitation programs, are not able to provide a quality and safe environment for many Victorians with co-occurring severe mental illness or suicide risk, due to infrastructure that is non-compliant with mental health sector standards, such as availability of individual rooms and non-ligature points, intervention programs that require a high level of social

skills and behavioural control, as well as a workforce that is not trained, skilled or resourced to manage their mental health needs.

- 97 Another key challenge for the Victorian AOD sector is that medical specialists are not a component of funded service delivery, meaning that there is limited medical support to undertake mental health and risk assessments, physical health checks and investigations, medication review and prescribing of effective pharmacotherapy. With limited GP access for this population due to skill gaps in primary care, this absence of a tertiary addiction specialist stream means that many patients receive substandard care, with limited access to medical and psychiatric reviews and evidence-based pharmacological and psychosocial interventions.

UNDERSTANDING THE AOD SYSTEM

The treatment approaches of the AOD and mental health sectors

a. *Engagement philosophies*

- 98 There are significant differences in treatment philosophies across the mental health and AOD sectors. A core tenet of the AOD system is that of a harm reduction approach. A key aspect of substance use disorders is ambivalence around change, driven by poor self-efficacy, competing health and social priorities, few alternate coping strategies and unresolved trauma or psychological issues. This means recognising where consumers are in terms of their stage of change, and the appropriate intervention needed to support them at that time. Clinicians within the AOD sector are skilled in working alongside consumers, with a focus on engagement using a motivational framework, and without the constraints of an involuntary paradigm and related system architecture.

- 99 In contrast, the public mental health system is heavily structured to manage risk in the context of an involuntary *Mental Health Act*. The resourcing of this system is firmly focussed at the pointy end of acute mental illness, with a particular focus on crisis management in the context of risk to consumers or the community. The system predominantly provides episodic care, with limited opportunity for long-term treatment or evidence-based therapies designed to address sustained remission and recovery. As such, the system is not designed to manage ambivalence and to work within an engagement framework, but to ensure consumers, families and the Victorian community remain safe.

b. *Potential lessons*

- 100 There are many components of the mental health system that would be invaluable for the AOD sector to learn from. These include well established quality and safety structures and processes, robust clinical governance, a distinct quality framework and related

standards, an articulated workforce structure with key competencies identified, and established mechanisms for supervision and clinical review.

- 101 The public mental health sector also works as a system, with coordination of activity, and clear oversight of its performance and quality, including a specific government office that is focussed on safety, quality and clinical guidance. In contrast, the AOD sector is largely governed as a collection of distinct services, with limited system oversight or coordination, or a focus on system performance and improvement.
- 102 In terms of the mental health system, I feel that there is much to learn from the treatment philosophy of the AOD sector, including its collaborative models, holistic focus, and orientation to remission and recovery as opposed to crisis and risk management.
- 103 The mental health system could enormously benefit from access to addiction psychiatrists, who are experts in understanding the relationship between drugs, addiction, mental illness and physical health, as well as related evidence-based pharmacological and psychological approaches. Addiction psychiatrists also understand the potential iatrogenic harms caused by many psychoactive medications, including benzodiazepines, amphetamines, antipsychotics and sleep medications, which are consistently associated with issues of diversion and misuse, as well as the increasing number of Victorian drug-related deaths. Addiction psychiatrists are an essential component of an integrated care system that supports mental health professionals with specialist advice and training in the safe prescribing of these medications, as well as ensuring consumers with mental illness receive ready access to opiate substitution pharmacotherapy and other evidence-based interventions.
- 104 While both sectors acknowledge the enormous importance of consumers and carers with lived experience, unfortunately it is only the mental health system that has dedicated funding for employment of a peer workforce across its system. This is a service gap that must be addressed.

Major gains in AOD sector service reform outside Victoria

- 105 Across Australia and internationally, there is consensus that comorbidity is the norm, and the lack of integration between mental health and AOD sectors disadvantages consumers, and results in poor outcomes and growing societal costs. As such, there have been multiple reviews and initiatives focussed on addressing this issue.¹⁰

¹⁰ Karapareddy V. A review of integrated care for concurrent disorders: Cost effectiveness and clinical outcomes (2019). *Journal of Dual Diagnosis*;15: 56-66.

Deady M, Barrett EL, Mills KL, Kay-Lambkin F, Haber P, Shand F, Baker A, Baillie A, Christensen H, Manns L, Teesson M. Effective models of care for comorbid mental illness and illicit substance

- 106 There are many lessons learnt from these multiple initiatives and I would like to draw the Commission's attention to the report published by the Sax Institute, as well as the models developed in Canada, US, New South Wales and Queensland.¹¹

YOUTH

Youth-specific risk factors

- 107 Early use of alcohol or drugs is associated with more frequent use during late adolescence, increased risk for later substance use disorders, as well as other health problems in early adulthood, such as injuries and the development of mental illness. Accessibility and availability of alcohol and drugs in the community, as well as prevailing cultural norms, are key drivers of substance use behaviours among young people. Peers also have a central role in the initiation and progression of alcohol and drug use, by influencing behaviour directly through providing opportunities to use, as well as indirectly by strengthening pro-substance use norms or modelling substance use behaviours. Other risk factors linked to harmful substance use during adolescence include genetic vulnerability, social disadvantage, child abuse and neglect, family breakdown, early school failure and favourable parental attitudes to alcohol or drug use.

Relationship between mental health and substance use disorders in young people

a. Differences with adults

- 108 In general, adolescents tend to recognise problems less readily than adults, present for treatment more frequently for drug use disorders than alcohol, report more binge and opportunistic substance use, and have higher rates of mental health problems. External pressures from family, school or legal settings are more likely to be a part of the reason for referral to treatment. Difference in choice of substances used between adults and young people is related to the varying finances, availability, access and social norms in those groups. For example, drinking heavily as a young person is more normalised than for a person in their late 30s with children and a career.

Barriers to help seeking and service access for young people

- 109 Seeking help early is widely recognised as a key protective factor, and promoting early and prompt treatment is critical for reducing the adverse impacts of mental health and

use: An Evidence Check review brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Mental Health and Drug and Alcohol Office.

¹¹ <https://www.thenationalcouncil.org/integrated-health-coe/about-us/>.

Deady M, Barrett EL, Mills KL, Kay-Lambkin F, Haber P, Shand F, Baker A, Baillie A, Christensen H, Manns L, Teesson M. Effective models of care for comorbid mental illness and illicit substance use: An Evidence Check review brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Mental Health and Drug and Alcohol Office.

substance use disorders. However, fewer than one in four Australian 16–24 year-olds with a current disorder access health services, with those experiencing a substance use disorder being the least likely to seek professional help. Rather than seeking professional help, research indicates that young people are keeping their problems to themselves or turning to their peers or key adults in their lives for help. This is despite evidence that many parents and peers have poor mental health literacy, as well as attitudes that do not promote recognition and appropriate help-seeking.

- 110 In addition, adolescents have knowledge, attitudes and beliefs about help-seeking and substance use that act as barriers to seeking professional help, and these are likely to have been established before the age of 13. Barriers identified include stigma, fears about lack of confidentiality, limited trust, lack of problem recognition, reliance on oneself, and concerns about helper characteristics. These help-seeking beliefs and preferences highlight the importance of building the mental health literacy of adolescents, including ensuring that they know when and how to assist their peers to access support.
- 111 Over the past decade, we have developed a school-based help-seeking intervention, MAKINGtheLINK, that teaches adolescents practical skills to help them support peers experiencing mental health or substance use issues.¹² This program addresses a number of critical gaps in existing school-based early intervention and health promotion activities, by focussing on exploring barriers to seeking help, teaching students the skills to overcome these barriers, and encouraging professional help-seeking. The program is novel in its emphasis on teaching practical steps for peers to become effective gatekeepers. However, while the focus on the program is primarily about supporting peers, improving students' mental health literacy and help-seeking skills is also a potentially effective means of increasing participants' help-seeking for their own problems. Indeed, a recent large NHMRC-funded trial we conducted in 21 Victorian schools found that students who received the program were more likely to subsequently seek professional help for their own mental health issues rather than informal support.¹³ This is a key finding, as it highlights the opportunity to help young people access evidence-based treatment earlier. MAKINGtheLINK is the only school-based intervention that has demonstrated that it is possible to change young people's help-seeking choices

¹² Lubman DI, Berridge BJ, Blee F, Jorm AF, Wilson CJ, Allen NB, McKay-Brown L, Priomos J, Cheetham A & Wolfe R (2016). A school-based health promotion programme to increase help-seeking for substance use and mental health problems: study protocol for a randomised controlled trial. *Trials*; 17: 393.

¹³ Lubman DI, Cheetham A, Sandral E, Wolfe R, Martin C, Blee F, Berridge BJ, Jorm AF, Wilson C, Allen NB, McKay-Brown L & Priomos J (2020). Twelve-month outcomes of MAKINGtheLINK: a cluster randomized controlled trial of a school-based program to facilitate help-seeking for substance use and mental health problems. *EClinicalMedicine*; 18: 100225.

and actual behaviours, and there is an opportunity to roll this evidence-based program out to Victorian schools as part of an integrated mental health strategy.

- 112 Research consistently shows that the stigma associated with substance use disorders leads to substantial delays in help-seeking – up to two decades.¹⁴ While there has been enormous investment in reducing stigma and service access for young people with mental health problems, with substantial growth in youth mental health services and funding for advocacy organisations, messaging around alcohol and drugs remains ambiguous. There are no public health campaigns promoting early help-seeking for alcohol use disorders, while national drug campaigns send the message that people who use drugs are aggressive and dangerous, and should be referred to police rather than health services. This situation is further exacerbated by extensive, and largely unregulated alcohol industry advertising, including aggressive social marketing campaigns to young people, that promote the idea that heavy alcohol consumption is the norm and core to socialising, relaxing and having fun. These mixed messages, coupled with prevailing social norms around the central role of alcohol in Australian life, result in many young people feeling at fault for developing an alcohol use disorder, and fearful of being judged.
- 113 If a young person is suicidal or depressed, there is clear public messaging and funding for promotion and advertising related to normalising early help-seeking and promoting the multiple options for seeking help, including helplines such as beyondblue, lifeline or eheadspace. This contrasts enormously with what is available in the AOD space, where there has been no public funding to promote or advertise help-seeking as a key health strategy, nor clear messaging about the options for getting help. For example, there has been no investment in advertising Directline, Victoria’s AOD helpline, as a first port of call for help, either through traditional channels or social media platforms that are heavily patronised by young people, despite significant investment in other Victorian mental health, family violence, cancer and quitline helpline services. This perpetuates the community belief, reinforced by negative media portrayals of addiction, that people with substance use disorders are the derelict drunk or the unconscious heroin junkie, and that treatment is ineffective and only for those who hit rock bottom. It is therefore unsurprising that most Victorians would not know that help is available for substance use disorders or where to easily seek support, with less than 10% of young Australians with substance use disorders currently seeking help.¹⁵ For those that do, what they receive is a lottery,

¹⁴ Chapman C. Delay to first treatment contact for alcohol use disorder (2015). *Drug and Alcohol Dependence*; 147: 116-121.

Wang PS. Delay and failure in treatment seeking after first onset of mental disorders in WHO’s World Mental Health Survey Initiative (2007). *World Psychiatry*; 6: 177-185.

¹⁵ Reavley NJ, Cvetkovski S, Jorm AF, Lubman DI (2010). Helpseeking for substance use, anxiety and affective disorders among young people: results from the 2007 Australian National Survey of Mental Health and Wellbeing. *Australian & New Zealand Journal of Psychiatry*; 44; 729-735.

dependent on the competency of the school welfare, helpline, GP or youth mental health service they contact. Integrated care is a rarity, and most helplines and health services do not have the capacity or competencies required to address youth substance use disorders.

Tailoring substance use disorder interventions and programs to young people

- 114 There is an established evidence base for the treatment of substance use disorders in young people. Services that can provide a range of treatment modalities and evidence-based interventions will be best placed to respond differentially, depending on the specific needs of the young person and their family. Family interventions are essential, particularly for younger adolescents, with the balance of individual to family interventions increasing as the young person develops and becomes more independent. Group psychological treatment should also be offered, while access to opiate substitution treatment and medical support for detoxification should be available, and if not possible within a youth service, links with addiction specialist services developed so that clinicians can support young people at the interface. Tailored smoking cessation services should also be available to young people who have initiated smoking and want to quit, in order to prevent long-term morbidity and mortality.
- 115 Treatment planning should be tailored for each young person, taking into account co-occurring disorders, developmental issues and the family and social environment. Often the opportunity to address substance use disorders arises while these other issues are being addressed, thus integrating substance use treatment into the overall system of care is recommended, especially if the young person is not actually seeking help for their substance use or their use is exacerbating other problems. Management of risk and co-occurring mental health disorders is essential and is often required before the substance use can be addressed meaningfully. Effective digital interventions, either standalone or in conjunction with face to face therapies, will be increasingly available to complement more established therapies in future years.

Other models for young people with substance use disorders

- 116 Services are best set up separately and specifically for young people, rather than integrated with adult services, to ensure a developmental and engagement-focussed approach. They need to be flexible and accessible as even small barriers to entry can discourage those most in need. Nimble and responsive systems are required. Waiting lists or periods between assessment and entry into service should be avoided. Comprehensive assessment that identifies not only substance-related issues but also other co-occurring problems remains the foundation of effective substance use treatment, however a focus on treatment engagement, with an emphasis on relationship building in

the early stages of entry into services is equally important, as there is little to be gained from assessing young people who do not then turn up for treatment.

A service to provide compulsory treatment to young people with substance use disorders

a. Merits and risks

117 The concept of a compulsory treatment option for young people with severe substance use disorders that do not respond to less intrusive and restrictive interventions has merit, but would need to balance the incursion of civil liberties and human rights with a strong evidence base for the effectiveness of the proposed approach. It would also need to have a clear governance framework to ensure the rights and autonomy of young people were protected.

118 There is currently limited evidence to support compulsory treatment for young people with substance use disorders as being any more effective than offering voluntary treatment. When compulsory treatment is provided, it is frequently much better resourced in terms of staffing, infrastructure and other supports, than traditional treatment settings. Before we consider providing compulsory treatment, we must make sure that the current treatment available is of the highest quality, underpinned by a robust evidence base and a highly skilled workforce. Compulsory treatment should not be a substitute for high quality AOD care, and must be supported by clear evidence of effectiveness.

b. Are those considerations different if the consumers also have comorbid mental health challenges?

119 Only if there are considerations related to criteria relevant to the Mental Health Act.

sign here ►



print name DANIEL IAN LUBMAN

date 28 May 2020



**Royal Commission into
Victoria's Mental Health System**

ATTACHMENT DL-1

This is the attachment marked 'DL-1' referred to in the witness statement of Professor Dan Lubman dated 28 May 2020.

CURRICULUM VITAE

Name: Daniel Ian Lubman

Present Work Address: Turning Point,
110 Church Street
Richmond, Victoria 3121 Australia

Academic Qualifications: *Physiology BSc (Hons)* 1989 (Manchester University, Class 2(I))
MB ChB 1992 (Manchester University)
PhD 1998 (Manchester University)
FRANZCP 2001
FACHAM 2003

Current appointment

- Executive Clinical Director, Turning Point, Eastern Health
- Professor of Addiction Studies and Services, Eastern Health Clinical School, Monash University
- Director, Monash Addiction Research Centre, Monash University

Career summary

Prof Lubman trained as a Psychiatrist and Addiction Medicine Specialist. He has published a substantial body of original work (>500 publications) that has helped to shape the field and led to policy and practice change. As Director of Turning Point, Prof Lubman heads Australia's leading national addiction treatment, research and training centre, providing policy advice, national research and training programs, and direct clinical care to patients and families across Australia. He is also the inaugural Director of the Monash Addiction Research Centre, a cross-faculty Monash University initiative, bringing together >150 inter-disciplinary researchers to deliver novel solutions to address addiction and its impacts.

Research support

Since 2004, Prof Lubman has obtained >\$40 million in research funding, including 25 major national competitive grants (18 NHMRC; 9 ARC) and >\$25 million in clinical treatment and training grants.

Contribution to the field

Prof Lubman has been at the forefront of human imaging work identifying key brain structures that are critically involved in the development and maintenance of addictive behaviour. This includes seminal work in the area of attentional bias, anhedonia, adolescent development and the impact of long-term cannabis use on brain structure and function. Prof Lubman has also led multiple clinical trials examining the effectiveness of pharmacological and psychological approaches for substance use and mental disorders (including smoking), as well as implementation studies related to their adoption within clinical settings, with the resulting products being embedded within many treatment services across Australia. He has led health services research related to addiction for the Victorian Government, including work in the areas of demand modelling, service planning, outcome monitoring, and the development of clinical tools and guidelines. Prof Lubman led the establishment of an internationally unique national surveillance system for alcohol, drug, mental health, self-harm and suicide in partnership with ambulance services across Australia, and has conducted multiple large cohort studies, including Patient Pathways, the largest Australian study of people accessing

alcohol and drug treatment services. He co-led the development of international mental health first aid guidelines for Problem Drinking and Problem Drug Use, as well as the award-winning school-based help-seeking program for substance use and mental health problems, MAKINGtheLINK, which is freely available, and has been adopted by many schools across Australia. His prevention work focusing on improving parenting strategies to reduce the risk of adolescent alcohol misuse has led to the development of freely available practical guidelines and an international first, tailored web-based intervention that supplements the 2009 NHMRC alcohol use guidelines. In recognition of his work, Prof Lubman has received multiple awards, including the *Senior Research Award* from the Royal Australian and New Zealand College of Psychiatrists (RANZCP), the *Senior Scientist Award* from the Australasian Professional Society on Alcohol and Other Drugs (APSAD) and an *Outstanding Achievement Award* from the International Society of Addiction Medicine (ISAM).

Community engagement and participation

Prof Lubman has contributed to the development of multiple national drug strategies, and is regularly contacted for policy advice and community comment. He has made numerous submissions to Government consultation processes related to alcohol, drugs and gambling, including giving evidence at the *Senate Select Committee on Mental Health* and *Joint Select Committee on Gambling Reform*. He sits on numerous State and Commonwealth Expert Reference Committees, including the Mental Health Ministerial Advisory Committee.

Professional involvement

As Chair of the RANZCP Faculty of Addiction Psychiatry from 2006-2017, Prof Lubman led the College's education, policy and media responses to addiction issues, and successfully redeveloped addiction postgraduate training for psychiatric trainees and fellows across Australia and New Zealand. He also established and co-convened the first four *International Medicine in Addiction* conferences, the largest addiction medical conference in the region.

International standing

Prof Lubman is an internationally renowned addiction treatment expert. His work has been highly cited (>15,000 times, *Google Scholar*), and is at the forefront of understanding pathways into and out of addiction, so as to inform the development of effective prevention, treatment and policy responses. He is regularly invited to present at national and international meetings.

Supervision and mentoring

Prof Lubman has supervised research students (Honours, Masters and PhD) from a number of Universities, as well as overseas fellows (>40 research projects supervised since 2003).

Peer review involvement

Prof Lubman has provided external review for NHMRC Project Grants since 1999, and has previously been a Member of the NHMRC Project Grants Review Panel. He provides external review for the ARC, Netherlands Organisation for Health Research and Development Project Grants as well as the UK Medical Research Council. He also provides peer-review for high-impact addiction, mental health and neuroscience journals, including *Addiction*, *JAMA Psychiatry*, *Journal of Neuroscience* and *Neuroscience & Biobehavioral Reviews*.

PUBLICATIONS (last 10 years):**Major Reports:**

1. Best D, Wilson A, Reed M, Harney A, Pahoki S, Kutin J, & **Lubman DI**. (2012). Youth cohort study: Young people's pathways through AOD treatment services. Victoria, Turning Point.
2. **Lubman D**, Peacock A, Droste N, Pennay A, Miller P, Bruno RB, Lloyd B, Hyder S, Roxburgh A, Wadds P, Tomsen S & Brown J (2013). Alcohol and Energy Drinks in NSW, NSW Government.
3. Miller PG, Pennay A, Droste N, Jenkinson R, Quinn B, Chikritzhs T, Tomsen SA, Wadds P, Jones SC, Palmer D, Barrie L, Lam T, Gilmore W & **Lubman DI**. (2013). Patron Offending and Intoxication in Night-Time Entertainment Districts (POINTED). Canberra: National Drug Law Enforcement Research Fund.
4. **Lubman D**, Manning V, Best D, Berends L, Mugavin J, Lloyd B, Lam T, Garfield J, Buykx P, Matthews S, Larner A, Gao C, Allsop S & Room R (2014). A Study of Patient Pathways in Alcohol and Other Drug Treatment. Victoria, Turning Point.
5. **Lubman DI**, Manning V, Best D, Berends L, Mugavin J, Lloyd B, Lam T, Garfield J, Buykx P, Matthews S, Larner A, Gao C, Allsop S & Room R. (2014). A study of patient pathways in alcohol and other drug treatment (Supplementary linkage component report. Fitzroy: Turning Point.
6. Hing N, Gainsbury S, Blaszczynski A, Wood R, **Lubman D** & Russell A. (2014) Interactive Gambling. Gambling Research Australia.
7. Best D, **Lubman DI**, Green R, Hunter B, Grynevych A, Flood M & Elliott M (2014). The development of a Quality Framework for Australian Government funded Drug and Alcohol Treatment Services. Victoria, Turning Point.
8. Barker F, Best D, Flood M, Hunter B, **Lubman D** & Rush B (2014). Performance management framework for the Victorian AOD sector. Fitzroy: Turning Point.
9. Hunter B, Bailey E, Flood M & **Lubman D** (2014). Review and update of the Victorian prison opioid substitution therapy program clinical and operational policy and procedures manual. Fitzroy: Turning Point.
10. **Lubman DI**, Rodda S, Hing N, Cheetham A, Cartmill T, Nuske E, Hodgins D & Cunningham J (2015). Gambler Self-Help Strategies: A Comprehensive Assessment of Self-Help Strategies and Actions. Gambling Research Australia.
11. Lloyd, B, Gao CX, Heilbronn C, **Lubman DI** (2015). Self-harm and mental health-related ambulance attendances in Australia: 2013 Data. Victoria: Turning Point.
12. Oakes J, Manning V, Rodda S, Flood M & **Lubman DI** (2016). Six-Step Brief Intervention to Reduce Distress and Increase Treatment Readiness in Problem Gamblers. Victoria: Turning Point.
13. Lam T, Lenton S, Chikritzhs T, Gilmore W, Liang W, Pandzic I, Ogeil R, Faulkner A, Lloyd B, **Lubman D**, Aiken A, Burns L, Mattick R, ACT Health, Olsen A, Bruno R, De Angelis O, Roche A, Fischer J, Trifonoff A, Midford R, Salom C, Alati R, Allsop S (2017). Young Australians' Alcohol Reporting System (YAARS): National Report 2016/17. Perth: National Drug Research Institute, Curtin University.
14. **Lubman DI**, Manning V, Dowling N, Rodda S, Lee S, Garde E, Merkouris S & Volberg R (2017). Problem gambling in people seeking treatment for mental illness. Victorian Responsible Gambling Foundation, Melbourne.
15. **Lubman DI**, Manning V & Cheetham A (2017). Informing alcohol and drug service planning in Victoria. Fitzroy: Turning Point.
16. **Lubman DI**, Amsing N & Houstone J (2017). Development of a National Quality Framework for Alcohol and Drug Treatment Services. Victoria, Turning Point.

17. Manning V, Arunogiri S, Frei M, Ridley K, Mroz K, Campbell S & **Lubman D**. (2018). Alcohol and other Drug Withdrawal: Practice Guidelines, 3rd ed. Richmond, Victoria: Turning Point.
18. Turning Point (2019). Beyond the Emergency: A national study of ambulance responses to men's mental health. Richmond, Victoria.

Book Chapters:

1. Hester R, **Lubman DI** & Yücel M (2010). The role of executive control in human drug addiction. In *Behavioral Neuroscience of Drug Addiction*. Self DW & Staley JK (eds). Springer; 301-318.
2. Hides L, Carroll S, **Lubman DI** & Baker A (2010). Brief motivational interviewing interventions for depression and anxiety. In *Oxford Guide to Low Intensity CBT Interventions*. Bennett-Levy J, Richards D, Farrand P, Christensen H, Griffiths K, Kavanagh K, Klein B, Lau MA, Proudfoot J, Ritterband L, Williams C & White J (eds). Oxford University Press; 177-186.
3. Kitchener BA, Jorm AF, **Lubman DI** (2011). Mental health - substance use first aid. In *Responding in mental health-substance use*. Cooper DB (ed). London, Radcliffe Publishing; 101-118.
4. Solowij N, Yücel M, Lorenzetti V & **Lubman DI** (2012). Does cannabis cause lasting brain damage? In *Marijuana and Madness (2nd edition)*. Castle DJ, Murray RM & D'Souza DC (eds). Cambridge University Press; 103-113.
5. Pennay A, **Lubman DI** & Reichert T (2012). Opportunistic interventions for methamphetamine misuse: Reducing the risks. In *Amphetamine Type Stimulants*. Allsop S & Lee N (eds). Melbourne, IP Communications; 241-253.
6. Baigent M & **Lubman DI** (2013). Substance use disorders. In *A Primer of Clinical Psychiatry (2nd edition)*. Castle DJ, Bassett D, King J & Gleason A (eds). Elsevier; 362-378.
7. Lorenzetti V, **Lubman DI**, Fornito A, Whittle S, Takagi MJ, Solowij N and Yücel M (2013). The impact of regular cannabis use on the human brain: A review of structural neuroimaging studies. In *Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders*. San Diego, Elsevier: 711-728.
8. Miller P, Pennay A, Droste N, Jenkinson R, Quinn B, Chikritzhs T, Tomsen S, Wadds P, Jones SC, Palmer D, Barrie L, Lam T, Gilmore W & **Lubman D** (2014). Patron Offending and Intoxication in Night-Time Entertainment Districts (POINTED). In *Stemming the Tide of Alcohol: Liquor licensing and the public interest*. Manton E, Room R, Giorgi C & Thorn M (eds). Melbourne, University of Melbourne; 211-223.
9. Arunogiri S, Frei M & **Lubman DI** (2015). Cannabis. In *Addiction Medicine*. Haber P, Day C & Farrell M (eds). Melbourne, IP Communications; 330-341.
10. Arunogiri S & **Lubman DI** (2016). Alcohol and cardiovascular risk. In *Handbook of Psychocardiology*. Alvarenga M & Bryne D (eds). Singapore, Springer; 119-140.
11. Rodda SN, Abbott MW, Dowling NA & **Lubman DI** (2016). Workforce Development and E-Competency in Mental Health Services. In *Workforce Development Theory and Practice in the Mental Health Sector*. Smith M & Jury A (eds). IGI Global; 284-301.
12. Savic M, Barker SF, Hunter B & **Lubman D** (2016). 'Holy shit, didn't realise my drinking was high risk': an analysis of the way risk is enacted through an online alcohol and drug screening intervention. In *Digitised Health, Medicine and Risk*. Lupton D (ed). London, Routledge; 93-119
13. Naim-Feil J, Arunogiri S, Spagnolo PA & **Lubman DI** (2016). Addiction. In *Developmental Disorders of the Brain*. Rinehart N, Bradshaw J & Enticott P (eds). Psychology Press; 208-230.

Peer-reviewed Journal Articles:

1. Baker A, **Lubman DI** & Hides L (2010). Smoking and schizophrenia: Treatment approaches within primary care. *Primary Psychiatry*; **17**: 49-54.

2. Hides L, Carroll S, Catania L, Cotton SM, Baker A, Scaffidi A & **Lubman DI** (2010). Outcomes of an integrated cognitive behaviour therapy (CBT) treatment program for co-occurring depression and substance misuse in young people. *Journal of Affective Disorders*; **121**: 169-174.
3. Scott RM, Hides L, Allen JS, Burke R & **Lubman DI** (2010). Depressive and anxiety symptomatology in ecstasy users: The relative impact of genes, trauma, life stress, and drug use. *Psychopharmacology*; **20**: 25-36.
4. **Lubman DI** and Berk M (2010). Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: Where is the evidence? *Acta Neuropsychiatrica*; **22**: 95-97.
5. Baker A, Hides L & **Lubman DI** (2010). Treatment of cannabis use among people with psychotic and depressive disorders: A systematic review. *Journal of Clinical Psychiatry*; **71**: 247-254.
6. Lorenzetti V, **Lubman DI**, Velakoulis D & Yücel M (2010). Pituitary gland volume among heroin users stabilised on substitution pharmacotherapy. *Drug and Alcohol Dependence*; **110**: 164-166.
7. **Lubman DI**, King J & Castle DJ (2010). Treating comorbid substance use disorders in schizophrenia. *International Review of Psychiatry*; **22**: 191-201.
8. Lorenzetti V, **Lubman DI**, Whittle S, Solowij N & Yücel M (2010). Structural MRI findings in long-term cannabis users: What do we know? *Substance Use and Misuse*; **45**: 1787-1808.
9. Takagi MJ, Yücel M & **Lubman DI** (2010). The dark side of sniffing: Paint colour affects intoxication experiences among adolescent inhalant users. *Drug and Alcohol Review*; **29**: 452-455.
10. Reavley NJ, Cvetkovski S, Jorm AF, **Lubman DI** (2010). Helpseeking for substance use, anxiety and affective disorders among young people: results from the 2007 Australian National Survey of Mental Health and Wellbeing. *Australian & New Zealand Journal of Psychiatry*; **44**: 729-735.
11. Cheetham A, Allen NB, Yücel M & **Lubman DI** (2010). The role of affective dysregulation in drug addiction. *Clinical Psychology Review*; **30**: 621-634.
12. **Lubman DI** and Baker A (2010). Managing cannabis and mental health issues within primary care. *Australian Family Physician*; **39**: 554-557.
13. Brown A, **Lubman DI** & Paxton S (2010). Sexual risk behaviour among young adults with first-episode psychosis. *Early Intervention in Psychiatry*; **4**: 234-242.
14. Hides L, Samet S & **Lubman DI** (2010). Cognitive behaviour therapy (CBT) for the treatment of co-occurring depression and substance use: Current evidence and directions for future research. *Drug and Alcohol Review*; **29**: 508-517.
15. Ryan SM, Jorm AF & **Lubman DI** (2010). Parenting factors associated with reduced adolescent alcohol use: a systematic review of longitudinal studies. *Australian & New Zealand Journal of Psychiatry*; **44**: 774-783.
16. Hunter B & **Lubman DI** (2010). Substance misuse – management in the older population. *Australian Family Physician*; **39**: 738-741.
17. Coulson CE, Williams LJ, Henry MJ, Berk M, **Lubman DI**, Brennan SL, Nicholson GC, Kotowicz MA, Korn S & Pasco JA (2010). Patterns of alcohol use and associated physical and lifestyle characteristics according to new Australian guidelines. *Australian & New Zealand Journal of Psychiatry*; **44**: 946-951.
18. Hart LM, Bouchier SJ, Jorm AF, Kanowski LG, Kingston AH, Stanley D & **Lubman DI** (2010). Development of mental health first aid guidelines for Aboriginal and Torres Strait Islander people experiencing problems with substance use: a Delphi study. *BMC Psychiatry*; **10**: 78.

19. Feil J, Sheppard D, Fitzgerald PB, Yücel M, **Lubman DI** & Bradshaw JL (2010). Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. *Neuroscience and Biobehavioral Reviews*; **35**: 248–275.
20. Yücel M, Zalesky A, Takagi MJ, Bora E, Fornito A, Ditchfield M, Egan GF, Pantelis C & **Lubman DI** (2010). White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. *Journal of Psychiatry and Neuroscience*; **35**: 409-412.
21. Robin R & **Lubman DI** (2010). Politics and science in classifying the dangers of drugs. *Evidence-Based Mental Health*; **13**: 97-99.
22. Takagi M, Yücel M, Cotton S, Baliz Y, Tucker A, Elkins K & **Lubman DI** (2011). Verbal memory, learning and executive functioning among young inhalant and cannabis users. *Journal of Studies on Alcohol and Drugs*; **72**: 96-105.
23. Brown A, **Lubman DI** & Paxton SJ (2011). Reducing sexually-transmitted infection risk in young people with first-episode psychosis. *International Journal of Mental Health Nursing*; **20**: 12-20.
24. Kingston AH, Morgan AJ, Jorm AF, Kitchener B, Kelly CM, Hall K, Hart LM & **Lubman DI** (2011). Helping someone with problem drug use: A Delphi consensus study of consumers, carers and clinicians. *BMC Psychiatry*; **11**: 3.
25. Ryan SM, Jorm AF, Kelly CM, Hart LM, Morgan AJ & **Lubman DI** (2011). Parenting strategies for reducing adolescent alcohol use: a Delphi consensus study. *BMC Public Health*; **11**: 13.
26. Berends L & **Lubman DI** (2011). Brief intervention in an emergency department reduces violence in the short term but not alcohol misuse in at-risk adolescents (commentary). *Evidence-Based Mental Health*; **14**: 20.
27. Berridge BJ, Hall K, Dillon P, Hides L & **Lubman DI** (2011). MAKINGtheLINK: a school-based health promotion strategy to increase helpseeking for cannabis and mental health issues among adolescents. *Early Intervention in Psychiatry*; **5**: 81-88.
28. Zipursky A, Whittle S, Yücel M, Lorenzetti V, Wood SJ, **Lubman DI**, Simmons JG & Allen NB (2011). Pituitary volume prospectively predicts internalizing symptoms in adolescence. *Journal of Child Psychology and Psychiatry*; **52**: 315-323.
29. Pennay A, **Lubman DI** & Miller P (2011). Combining energy drinks and alcohol: A recipe for trouble? *Australian Family Physician*; **40**: 104-107.
30. Hunter B, **Lubman DI** & Barratt M (2011). Alcohol and drug misuse in the elderly. *Australian & New Zealand Journal of Psychiatry*; **45**: 343.
31. McCann TV, **Lubman DI** & Clark E (2011). First-time primary caregivers' experiences of caring for young adults with first-episode psychosis. *Schizophrenia Bulletin*; **37**: 381-388.
32. McCann TV, **Lubman DI** & Clark E (2011). Responding to stigma: First-time caregivers of young people with first-episode psychosis. *Psychiatric Services*; **62**: 548-550.
33. Takagi M, **Lubman DI** & Yücel M (2011). Solvent-induced leukoencephalopathy: a disorder of adolescence? *Substance Use and Misuse*; **46 Suppl 1**: 95-98.
34. **Lubman DI**, Hall K, Pennay A & Rao S (2011). Managing substance use and borderline personality disorder within primary care: an integrated approach. *Australian Family Physician*; **40**: 376-381.
35. McCann TV, **Lubman DI** & Clark E (2011). First-time primary caregivers' experience accessing first-episode psychosis services. *Early Intervention in Psychiatry*; **5**: 156-162.
36. Solowij N, Jones KA, Rozman ME, Davis S, Ciarrochi J, Heaven P, **Lubman DI** & Yücel M (2011). Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. *Psychopharmacology*; **216**: 131-144.
37. Reavley NJ, Jorm AF, McCann TV & **Lubman DI** (2011). Alcohol consumption in tertiary education students. *BMC Public Health*; **11**: 545.

38. Gibbie T, Hides L, Cotton S, **Lubman DI**, Aitken C & Hellard M (2011). The relationship between personality disorders and mental health, substance use severity and quality of life among injecting drug users. *Medical Journal of Australia*; **195**: S16-S21.
39. Hides L, Elkins KS, Scaffidi A, Cotton SM, Carroll S & **Lubman DI** (2011). Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse? *Medical Journal of Australia*; **195**: S31-S37.
40. McKetin R, **Lubman DI**, Lee NM, Ross JE & Slade TN (2011). Major depression among methamphetamine users entering drug treatment programs. *Medical Journal of Australia*; **195**: S51-S55.
41. Pennay A, **Lubman DI**, Maclean S (2011). Risky drinking among young Australians – causes, effects and implications for GPs. *Australian Family Physician*; **40**: 584-588.
42. Pennay A, Cameron J, Reichert T, Strickland H, Lee NK, Hall K & **Lubman DI** (2011). A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. *Journal of Substance Abuse Treatment*; **41**: 363-373.
43. Solowij N, Yücel M, Respondek C, Whittle S, Lindsay E, Pantelis C & **Lubman DI** (2011). Cerebellar white matter reduction in cannabis users with and without schizophrenia. *Psychological Medicine*; **41**: 2349-2359.
44. Yap MBH, Jorm AF, Bazley RC, Kelly CM, Ryan SM & **Lubman DI** (2011). Web-based parenting program to prevent adolescent alcohol misuse: rationale and development. *Australasian Psychiatry*; **19**: 339-344.
45. Jones KA, Nielsen S, Bruno R, Frei M & **Lubman DI** (2011). Benzodiazepines: Their role in aggression and why GPs should prescribe with caution. *Australian Family Physician*; **40**: 862-865.
46. Brown A, **Lubman DI** & Paxton S (2011). Psychosocial risk factors for inconsistent condom use in young people with first-episode psychosis. *Community Mental Health Journal*; **47**: 679-687.
47. McKetin R & **Lubman DI** (2011). Heavy stimulant use remains a significant health concern for Australia. *Medical Journal of Australia*; **195**: 565-566.
48. Takagi M, **Lubman DI**, Cotton S, Baliz Y, Tucker A & Yücel M (2011). Executive control among adolescent inhalant and cannabis users. *Drug and Alcohol Review*; **30**: 629-637.
49. McCann T, **Lubman DI** & Clark E (2012). Primary caregivers' satisfaction with clinicians' response to them as informal carers of young people with first-episode psychosis: a qualitative study. *Journal of Clinical Nursing*; **21**: 224-231.
50. Bora E, Yücel M, Fornito A, Pantelis C, Harrison B, Cochi L, Pell G & **Lubman DI** (2012). White matter microstructure in opiate addiction. *Addiction Biology*; **17**: 141-148.
51. Verdejo-García A, **Lubman DI**, Schwerk A, Roffel K, Vilar-López R, MacKenzie T & Yücel M (2012). Effect of craving induction on inhibitory control in opiate dependence. *Psychopharmacology*; **219**: 519-526.
52. Solowij N, Jones K, Rozman M, Davis S, Ciarrochi J, Heaven P, Pesa N, **Lubman DI** & Yücel M (2012). Reflection impulsivity in adolescent cannabis users: A comparison with alcohol-using and non-substance-using adolescents. *Psychopharmacology*; **219**: 575-586.
53. Heilbronn CE, Lloyd B, McElwee P, Eade A & **Lubman DI** (2012). Quetiapine-related harms are on the rise (letter). *Australian & New Zealand Journal of Psychiatry*; **46**: 279-280.
54. Yücel M, Bora E, **Lubman DI**, Solowij N, Brewer WJ, Cotton S, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD & Pantelis C (2012). The impact of cannabis use on cognitive functioning in patients with psychosis: new data and meta-analysis of existing findings. *Schizophrenia Bulletin*; **38**: 316-330.

55. Fraser S, Hides L, Philips L, Proctor D & **Lubman DI** (2012). Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. *Schizophrenia Research*; **136**: 110-115.
56. Cheetham A, Allen NB, Whittle S, Simmons J, Yücel M & **Lubman DI** (2012). Orbitofrontal volumes in early adolescence predict initiation of cannabis use: A four-year longitudinal and prospective study. *Biological Psychiatry*; **71**: 684-92.
57. Pennay A & **Lubman DI** (2012). Energy drinks: health risks and toxicity (letter). *Medical Journal of Australia*; **196**: 442.
58. Yücel M, Fornito A, Youssef G, Dwyer D, Whittle S, Wood SJ, **Lubman DI**, Simmons J, Pantelis C & Allen NB (2012). Inhibitory control in young adolescents: the role of sex, intelligence, and temperament. *Neuropsychology*; **26**: 347-356.
59. McCann TV, **Lubman DI** & Clark E (2012). The experience of young people with depression: a qualitative study. *Journal of Psychiatric and Mental Health Nursing*; **19**: 334-340.
60. Baker AL, Thornton L, Hiles S, Hides L & **Lubman DI** (2012). Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: A systematic review. *Journal of Affective Disorders*; **139**: 217-229.
61. Gilligan C, Kypri K, **Lubman DI** (2012). Changing parental behaviour to reduce risky drinking among adolescents: Current evidence and future directions. *Alcohol and Alcoholism*; **47**: 349-354.
62. Best D & **Lubman DI**. The emergence of a recovery movement for alcohol and drug dependence (letter). *Australian & New Zealand Journal of Psychiatry*; **46**: 586.
63. Harding IH, Solowij N, Harrison BJ, Takagi M, Lorenzetti V, **Lubman DI**, Seal ML, Pantelis C & Yücel M (2012). Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. *Neuropsychopharmacology*; **37**: 1923-1933.
64. O'Connor DA, Rossiter S, Yücel M, **Lubman DI** & Hester R (2012). Successful inhibitory control over an immediate reward is associated with attentional disengagement in visual processing areas. *Neuroimage*; **62**: 1841-1847.
65. Zalesky A, Solowij N, Yücel M, **Lubman DI**, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C & Seal M (2012). Effect of long-term cannabis use on axonal fiber connectivity. *Brain*; **135**: 2245-2255.
66. McCann T & **Lubman DI** (2012). Young people with depression and their satisfaction with the quality of care they receive from a primary care youth mental health service: A qualitative study. *Journal of Clinical Nursing*; **21**: 2179-2187.
67. Pennay A & **Lubman DI** (2012). Alcohol and energy drinks: A pilot study exploring patterns of consumption, social contexts, benefits and harms. *BMC Research Notes*; **5**: 369.
68. McCann TV & **Lubman DI** (2012). Young people with depression and their experience accessing an enhanced primary care service for youth with emerging mental health problems: a qualitative study. *BMC Psychiatry*; **12**: 96.
69. Best D & **Lubman DI** (2012). The Recovery Paradigm: A model of hope and change for alcohol and drug addiction. *Australian Family Physician*; **41**: 593-597.
70. Rodda S & **Lubman DI** (2012). Ready to Change: A scheduled telephone counselling program for problem gambling. *Australasian Psychiatry*; **20**: 338-342.
71. Hall K, Gibbie T & **Lubman DI** (2012). Motivational interviewing techniques: Facilitating behaviour change in the general practice setting. *Australian Family Physician*; **41**: 660-667.
72. Rodda S, **Lubman DI** & Latage K (2012). Problem gambling: aetiology, identification and treatment. *Australian Family Physician*; **41**: 725-729.
73. Baker AL, Hiles S, Thornton L, Hides L & **Lubman DI** (2012). Psychological and service interventions for alcohol misuse among people with co-occurring psychotic disorders: A systematic review. *Acta Psychiatrica Scandinavica*; **126**: 243-255.

74. McCann TV, **Lubman DI** & Clark E (2012). Views of young people with depression about family and significant other support: interpretative phenomenological analysis study. *International Journal of Mental Health Nursing*; **21**: 453-461.
75. McKetin R, Najman JM, Baker A, **Lubman DI**, Dawe S, Ali R, Lee NK, Mattick RP & Mamun A (2012). Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). *Addiction*; **107**: 1998-2008.
76. Zimmermann A, **Lubman DI** & Cox M (2012). Tobacco, caffeine, alcohol and illicit substance use among consumers of a national community managed mental health service. *Mental Health and Substance Use*; **5**: 287-302.
77. Duncan JR, Dick ALW, Egan G, Kolbe S, Gavrilescu M, Wright D, **Lubman DI** & Lawrence AJ (2012). Adolescent toluene inhalation in rats affects white matter maturation with the potential for recovery following abstinence. *PLoS One*; **7**: e44790.
78. Zimmermann A, **Lubman DI** & Cox M (2012). Tobacco, caffeine, alcohol and illicit substance use among consumers of a national psychiatric disability support service. *International Journal of Mental Health & Addiction*; **10**: 722-736.
79. Rodda S & **Lubman DI** (2012). Preoccupation, gambling and the DSM-V (letter). *International Gambling Studies*; **12**: 421-422.
80. Pennay A & **Lubman DI** (2012). More Australian research needed into alcohol and energy drinks (letter). *Drug and Alcohol Review*; **31**: 928-929.
81. Hides L, Carroll S, Scott R, Cotton S, Baker A & **Lubman DI** (2013). Quik Fix: A randomised controlled trial of an enhanced brief motivational interviewing (BMI) intervention for alcohol/cannabis and psychological distress in young people. *Psychotherapy and Psychosomatics*; **82**: 122-124.
82. Scott RM, Hides L, Allen JS & **Lubman DI** (2013). Subacute effects of ecstasy on mood: An exploration of associated risk factors. *Journal of Psychopharmacology*; **27**: 53-61.
83. Solowij N, Mark Walterfang M, **Lubman DI**, Whittle S, Lorenzetti V, Stynerf M, Velakoulis D, Pantelis C, Yücel M (2013). Alteration to hippocampal shape in cannabis users with and without schizophrenia. *Schizophrenia Research*; **143**: 179-184.
84. Best D, Wilson A, Reed M, Lloyd B, Eade A & **Lubman DI** (2013). Alprazolam and wider benzodiazepine misuse in Australia – sources of supply and evidence of harms (letter). *Australian and New Zealand Journal of Psychiatry*; **47**: 94-95.
85. Vilar-Lopez R, Takagi M, **Lubman DI**, Cotton SM, Bora E, Verdejo-Garcia A & Yücel M (2013). The effects of inhalant misuse on attentional networks. *Developmental Neuropsychology*; **38**: 126-136.
86. Miller P, Pennay A, Jenkinson R, Droste N, Chikritzhs T, Tomsen S, Wadds P, Jones SC, Palmer D, Barrie L & **Lubman DI** (2013). Patron offending and intoxication in night time entertainment districts (POINTED): A study protocol. *International Journal of Alcohol and Drug Research*; **2**: 69-76.
87. Verdejo-Garcia A, **Lubman DI**, Roffel K, Vilar-Lopez R, Bora E, MacKenzie T & Yücel M (2013). Cingulate biochemistry in heroin users on substitution pharmacotherapy. *Australian and New Zealand Journal of Psychiatry*; **47**: 244-249.
88. McKetin R, **Lubman DI**, Dawe S, Ali R & Baker A (2013). Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. *JAMA Psychiatry*; **70**: 319-324.
89. Cotton SM, McCann TV, Gleeson JF, Crisp K, Murphy BP & **Lubman DI** (2013). Coping strategies in carers of young people with a first episode of psychosis. *Schizophrenia Research*; **146**: 118-124.

90. Savic M, Best D, Berends L & **Lubman DI** (2013). Standardized screening measures for alcohol and other drug problems: Completion rates and impact on treatment motivation. *Alcoholism Treatment Quarterly*; **31**: 224-240.
91. Berends L & **Lubman DI** (2013). Obstacles to alcohol and drug care: Are Medicare Locals the answer. *Australian Family Physician*; **42**: 339-342.
92. Rodda S, **Lubman DI**, Dowling N, Baugh A & Jackson A (2013). Web-based counseling for problem gambling: exploring motivations and recommendations. *Journal of Medical Internet Research*; **15**: e99.
93. Coulson CE, Williams LJ, Brennan SL, Berk M, Kotowicz MA, **Lubman DI** & Pasco JA (2013). Alcohol consumption and body composition in a population-based sample of elderly Australian men. *Aging Clinical and Experimental Research*; **25**: 183-192.
94. Scott RM, Hides L, Allen JS & **Lubman DI** (2013). Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users. *Addictive Behaviors*; **38**: 2465-2472.
95. Best D, Savic M, Beckwith M, Honor S, Karpusheff J & **Lubman DI** (2013). The role of abstinence and activity in the quality of life of drug users engaged in treatment. *Journal of Substance Abuse Treatment*; **45**: 273-279.
96. Rodda S, **Lubman DI**, Dowling NA & McCann TV (2013). Motivations for using online counselling among family and friends impacted by problem gambling. *Asian Journal of Gambling Issues and Public Health*; **3**: 12.
97. Baker S, Yücel M, Fornito A, Allen NB & **Lubman DI** (2013). A systematic review of diffusion weighted MRI studies of white matter microstructure in adolescent substance users. *Neuroscience & Biobehavioral Reviews*; **37**: 1713-1723.
98. Wilson AS, Best DW, Savic M & **Lubman DI** (2013). Online screening for alcohol and other drug problems: An acceptable method for accessing help (letter). *Medical Journal of Australia*; **199**: 170.
99. Heilbronn CE, Lloyd B, McElwee P, Eade A & **Lubman DI** (2013). Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. *Drug and Alcohol Review*; **32**: 405-411.
100. Whittle S, Dennison M, Vijayakumar N, Simmons JG, Yücel M, **Lubman DI**, Pantelis C & Allen NB (2013). Childhood maltreatment and psychopathology affect brain development during adolescence. *Journal of the American Academy of Child and Adolescent Psychiatry*; **52**: 940-952.
101. Takagi M, **Lubman DI**, Walterfang M, Barton S, Reutens D, Wood A & Yücel M (2013). Corpus callosum size and shape alterations in adolescent inhalant users. *Addiction Biology*; **18**: 851-854.
102. Lloyd B, Barratt M, Ferris J, Best D & **Lubman DI** (2013). Factors influencing mortality among alcohol and drug treatment clients in Victoria, Australia: the role of demographic and substance use characteristics. *Australian & New Zealand Journal of Psychiatry*; **47**: 859-867.
103. Heilbronn CE, Gao CX, Lloyd B, Smith K, Best D & **Lubman DI** (2013). Trends in amphetamine-related harms in Victoria (letter). *Medical Journal of Australia*; **199**: 395.
104. Savic M, Best D, Rodda S & **Lubman DI** (2013). Exploring the focus and experiences of smartphone applications for addiction recovery. *Journal of Addictive Diseases*; **32**: 310-319.
105. McCann TV, **Lubman DI**, Cotton SM, Murphy B, Crisp K, Catania L, Marck C & Gleeson JFM (2013). A randomized controlled trial of bibliotherapy for carers of young adults with first-episode psychosis. *Schizophrenia Bulletin*; **39**: 1307-1317.
106. Berends L, **Lubman DI** (2013). Interactions between alcohol and prescription medications (reply). *Australian Family Physician*; **42**: 522.
107. Arungoli S, Foo, L, Frei M & **Lubman DI** (2013). Managing opioid dependence in pregnancy - A general practice perspective. *Australian Family Physician*; **42**: 713-716.

108. Lewis AJ, Bertino MD, Skewes J, Shand L, Borojevic N, Knight T, **Lubman DI** & Toumbourou JW (2013). Adolescent depressive disorders and family based interventions in the family options multicenter evaluation: study protocol for a randomized controlled trial. *Trials*; **14**: 384.
109. Garfield JB, **Lubman DI** & Yücel M (2014). Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. *Australian and New Zealand Journal of Psychiatry*; **48**: 36-51.
110. Best D, White E, Cameron J, Guthrie G, Hunter B, Hall K, Leicester S & **Lubman DI** (2014). A model for predicting clinician satisfaction with clinical supervision. *Alcoholism Treatment Quarterly*; **32**: 67-78.
111. Foo L, **Lubman DI**, Frei M & Arunogiri S (2014). An audit examining the impact of a training session on interest in prescribing opioid maintenance treatment among psychiatrists and trainees (letter). *Australasian Psychiatry*; **22**: 94.
112. Naim-Feil J, Fitzgerald PB, Bradshaw JL, **Lubman DI** & Sheppard D (2014). Neurocognitive deficits, craving and abstinence among alcohol-dependent individuals following detoxification. *Archives of Clinical Neuropsychology*; **29**: 26-37.
113. Cheetham A, Allen NB, Whittle S, Simmons J, Yücel M & **Lubman DI** (2014). Volumetric differences in the anterior cingulate cortex prospectively predict alcohol-related problems in adolescence. *Psychopharmacology*; **231**: 1731-1742.
114. Lorenzetti V, Solowij N, Fornito A, **Lubman DI** & Yücel M (2014). The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. *Current Pharmaceutical Design*; **20**: 2138-2167.
115. Best DW, Wilson AS, MacLean S, Savic M, Reed M, Bruun A & **Lubman DI** (2014). Patterns of family conflict and their impact on substance use and psychosocial outcomes in a sample of young people in treatment. *Vulnerable Children and Youth Studies*; **9**: 114-122.
116. McKetin R, **Lubman DI**, Najman JM, Dawe S, Butterworth P, Baker AL (2014). Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. *Addiction*; **109**: 798-806.
117. Thompson L, Pennay A, Zimmerman A, Cox M & **Lubman DI** (2014). "Clozapine makes me quite drowsy, so when I wake up in the morning those first cups of coffee are really handy": an exploratory qualitative study of excessive caffeine consumption among individuals with schizophrenia. *BMC Psychiatry*; **14**: 116.
118. Rodda S & **Lubman DI** (2014). The challenge of routine follow-up in e-mental health services (letter). *Australian and New Zealand Journal of Psychiatry*; **48**: 488-489.
119. Dowling N, Rodda S, **Lubman DI** & Jackson A (2014). The impacts of problem gambling on concerned significant others accessing web-based counseling. *Addictive Behaviors*; **39**: 1253-1257.
120. Best D, **Lubman DI**, Savic M, Wilson A, Dingle G, Haslam A, Haslam C & Jetten J (2014). Social and transitional identity: exploring social networks and their significance in a therapeutic community setting. *Therapeutic Communities*; **35**: 10-20.
121. Peacock A, Pennay A, Droste N, Bruno R & **Lubman DI** (2014). 'High' Risk? A systematic review of the acute outcomes of mixing alcohol with energy drinks. *Addiction*; **109**: 1612-1633.
122. Droste N, Tonner L, Zinkiewicz L, Pennay A, **Lubman DI** & Miller P (2014). Combined alcohol and energy drink use: Motivations as predictors of consumption patterns, risk of alcohol dependence and experience of injury and aggression. *Alcoholism: Clinical and Experimental Research*; **38**: 2087-2095.
123. Savic M, Barker SF, Best D & **Lubman DI** (2014). Alcohol problems amongst migrants in substance use treatment: the role of drinking patterns in countries of birth. *Australian Journal of Primary Health*; **20**: 220-221.

124. Pennay A, **Lubman DI** & Frei M (2014). Alcohol: prevention, policy and primary care responses. *Australian Family Physician*; **43**: 356-361.
125. McCann TV & **Lubman DI** (2014). Qualitative process evaluation of a problem-solving guided self-help manual for family carers of young people with first-episode psychosis. *BMC Psychiatry*; **14**: 168.
126. Miller P, Pennay A, Droste N, Butler E, Jenkinson R, Hyder S, Quinn B, Chikritzhs T, Tomsen S, Wadds P, Jones SC, Palmer D, Barrie L, Lam T, Gilmore W & **Lubman DI** (2014). A comparative study of blood alcohol concentrations in Australian night-time entertainment districts. *Drug and Alcohol Review*; **33**: 338-345.
127. Lewis AJ, Bertino MD, Bailey CM, Skewes J, **Lubman DI** & Toumbourou JW (2014). Depression and suicidal behavior in adolescents: a multi-informant and multi-methods approach to diagnostic classification. *Frontiers in Psychology*; **5**: 766.
128. Gainsbury SM, Russell A, Hing N, Wood R, **Lubman D** & Blaszczynski A (2014). The prevalence and determinants of problem gambling in Australia: Assessing the impact of interactive gambling and new technologies. *Psychology of Addictive Behaviors*; **28**: 769-779.
129. Takagi M, **Lubman DI**, Cotton SM, Verdejo-García A, Vilar-López R & Yücel M (2014). A signal detection analysis of executive control performance among adolescent inhalant and cannabis users *Substance Use and Misuse*; **49**: 1920-1927.
130. Hing N, Cherney L, Blaszczynski A, Gainsbury SM & **Lubman DI** (2014). Do advertising and promotions for online gambling increase gambling consumption? An exploratory study. *International Gambling Studies*; **14**: 394-409.
131. Albrecht B, Staiger PK, Hall K, Miller P, Best D & **Lubman DI** (2014). Benzodiazepine use and aggressive behaviour: A systematic review. *Australian and New Zealand Journal of Psychiatry*; **48**: 1096-1114.
132. **Lubman DI**, Droste N, Pennay A, Hyder S & Miller P (2014). High rates of alcohol consumption and related harm at Schoolies Week: a portal study. *Australian and New Zealand Journal of Public Health*; **38**: 536-541.
133. Pillay I, Best D & **Lubman DI** (2014). Exploring clinician attitudes to addiction recovery in Victoria, Australia. *Alcoholism Treatment Quarterly*; **32**: 375-392.
134. Hong SB, Choi EJ, Kim HH, Suh JE, Takagi MJ, **Lubman DI**, Kim JW, Kim CD, Yi SH & Yücel M (2014). Decreased thalamic volumes in adolescent inhalant users from Korea and Australia. *World Journal of Biological Psychiatry*; **15**: 636-640.
135. Rodda S & **Lubman DI** (2014). Characteristics of gamblers using a national online counselling service for problem gambling. *Journal of Gambling Studies*; **30**: 277-289.
136. Arunogiri S, Frei M, **Lubman D** (2014). Persistent noncancer pain in patients with addiction: reflecting on the challenges. *Medicine Today*; **15**: 58-61.
137. Coulson CE, Williams LJ, Berk M, **Lubman DI**, Quirk SE & Pasco JA (2014). Association between alcohol consumption and self-reported depression among elderly Australian men. *Geriatric Mental Health Care*; **2**: 3-8.
138. Rodda SN, Hing N & **Lubman DI** (2014). Improved outcomes following contact with a gambling helpline: the impact of gender on barriers and facilitators. *International Gambling Studies*; **14**: 318-329.
139. Pennay A, Miller P, Busija L, Jenkinson R, Droste N, Quinn B, Jones S & **Lubman DI** (2015). 'Wide Awake Drunkenness'? Investigating the association between stimulant use and alcohol intoxication in the night time economy. *Addiction*; **110**: 356-365.
140. Lorenzetti V, Solowij N, Whittle SL, Fornito A, **Lubman DI**, Pantelis C & Yücel M (2015). Gross morphological changes with chronic, heavy cannabis use. *British Journal of Psychiatry*; **206**: 77-78.

141. **Lubman DI**, Cheetham A & Yücel M (2015). Cannabis and adolescent brain development. *Pharmacology & Therapeutics*; 148: 1-16.
142. Gainsbury SM, Russell A, Hing N, Wood R, **Lubman D** & Blaszczynski A (2015). How the Internet is changing gambling: Findings from an Australian prevalence survey. *Journal of Gambling Studies*; **31**: 1-15.
143. Odell MS, Frei MY, Gerostamoulos D, Chu M & **Lubman DI** (2015). Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use. *Forensic Science International*; **249**: 173-180.
144. Best D, Hall K, Guthrie A, Abbatangelo M, Hunter B & **Lubman DI** (2015). Development and implementation of a structured intervention for alcohol use disorders for telephone helpline services. *Alcoholism Treatment Quarterly*; **33**: 118-131.
145. Yap MBH, Jorm AF & **Lubman DI** (2015). What are parents doing to reduce adolescent alcohol misuse? Evaluating concordance with Parenting Guidelines for Adolescent Alcohol Use. *BMC Public Health*; **15**: 114.
146. Rodda SN, **Lubman DI**, Iyer R, Gao CX & Dowling NA (2015). Subtyping based on readiness and confidence: the identification of help-seeking profiles for gamblers accessing web-based counseling. *Addiction*; **110**: 494-501.
147. Lam T, Lenton SR, Burns L, Aiken A, Ogeil R, Gilmore WT, Chikritzhs TN, Lloyd B, **Lubman DI**, Mattick R, Allsop SJ (2015). Alcohol policy impact on young risky drinkers and their support for proposed measures. *Australian and New Zealand Journal of Public Health*; **39**: 129-134.
148. Peacock A, Droste N, Pennay A, **Lubman DI**, Miller P, Newcombe D & Bruno R (2015). Self-reported risk-taking behaviour during matched frequency sessions of alcohol versus combined alcohol and energy drinks: does co-ingestion increase risk-taking? *Alcoholism: Clinical and Experimental Research*; **39**: 911-918.
149. Garfield JB, Allen NB, Cheetham A, Simmons JG & **Lubman DI** (2015). Attention to pleasant stimuli in early adolescence predicts alcohol-related problems in mid-adolescence. *Biological Psychology*; **108**: 43-50.
150. Cheetham A, Allen NB, Schwartz O, Simmons JG, Whittle S, Byrne M, Sheeber L & **Lubman DI** (2015). Affective behavior and temperament predict the onset of smoking in adolescence. *Psychology of Addictive Behaviors*; **29**: 347-354.
151. Peacock A, Droste N, Pennay A, Miller P, **Lubman DI** & Bruno R (2015). Typology of alcohol mixed with energy drink consumers: Motivations for use. *Alcoholism: Clinical and Experimental Research*; **39**: 1083-1092.
152. Pennay A, Cheetham A, Droste N, Miller P, Lloyd B, Pennay D, Dowling N, Jackson A & **Lubman DI** (2015). An examination of the prevalence, consumer profiles and patterns of energy drink use, with and without alcohol, in Australia. *Alcoholism: Clinical and Experimental Research*; **39**: 1485-1492.
153. Baker S, **Lubman DI**, Yücel M, Allen N, Whittle S, Fulcher B, Zalesky A & Fornito A (2015). Maturation of brain network hub connectivity in late adolescence. *Journal of Neuroscience*; **35**: 9078-9087.
154. Ogeil RP, Heilbronn C, Lloyd B & **Lubman DI** (2015). Benefits and challenges to the implementation of real-time prescription monitoring. *Medicine Today*; **16**: 65-68.
155. Hing N, Cherney L, Gainsbury S, **Lubman DI**, Wood R & Blaszczynski A (2015). Maintaining and losing control during internet gambling: A qualitative study of gamblers' experiences. *New Media and Society*; **17**: 1075-1095.
156. Berends L, Lerner A & **Lubman DI** (2015). Delivering opioid maintenance treatment in rural and remote settings. *Australian Journal of Rural Health*; **23**: 201-206.

157. Arunogiri S & **Lubman DI** (2015). Anxiety and substance use disorders: A worrying combination. *Australasian Psychiatry*; **23**: 382-387.
158. Kaar SJ, Gao CX, Lloyd B, Smith K & **Lubman DI** (2015). Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. *Drug and Alcohol Dependence*; **155**: 24-30.
159. Arunogiri S, Gao CX, Lloyd B, Smith K & **Lubman DI** (2015). The role of methamphetamines in psychosis-related ambulance presentations (letter). *Australian and New Zealand Journal of Psychiatry*; **49**: 939-940.
160. Rodda SN, **Lubman DI**, Cheetham A, Dowling NA & Jackson AC (2015). Single session web-based counselling: A thematic analysis of content from the perspective of the client. *British Journal of Guidance & Counselling*; **43**: 117-130.
161. Yücel M, Whittle S, Youssef GJ, Kashyap H, Simmons JG, Schwartz O, **Lubman DI**, Allen NB (2015). The influence of sex, temperament, risk taking behavior and mental health on gambling behavior: a longitudinal study of youth. *International Gambling Studies*; **15**: 108-123.
162. Berridge BJ, Cheetham A, McKay-Brown L & **Lubman DI** (2015). Improving help-seeking amongst adolescents: A school-based intervention (letter). *Australian and New Zealand Journal of Psychiatry*; **49**: 945-946.
163. Beckwith M, Best DW, Perryman C, Dingle G & **Lubman DI** (2015). Predictors of flexibility in social identity among people entering a therapeutic community for substance abuse. *Alcoholism Treatment Quarterly*; **33**: 93-104.
164. Ryan SM, Jorm AF, Toumbourou JW & **Lubman DI** (2015). Parental and family factors associated with service use by young people with mental health problems: a systematic review. *Early Intervention in Psychiatry*; **9**: 433-446.
165. Mawson E, Best D, Beckwith M, Dingle GA & **Lubman DI** (2015). Social identity, social networks and recovery capital in emerging adulthood: A pilot study. *Substance Abuse Treatment, Prevention and Policy*; **10**: 45.
166. **Lubman D** & Jenkins P (2015). New College policy and advocacy work contributes to addressing methamphetamine-related harms in Australia and New Zealand. *Australasian Psychiatry*; **23**: 719.
167. McNair R, Pennay A, Hughes T, Brown R, Leonard W & **Lubman DI** (2016). A model for lesbian, bisexual and queer-related influences on alcohol consumption and implications for policy and practice. *Culture, Health & Sexuality*; **18**: 405-421.
168. Youssef G, Whittle S, Allen NB, **Lubman DI**, Simmons JG & Yücel M (2016). Cognitive control as a moderator of temperamental motivations toward adolescent risk-taking behavior. *Child Development*; **87**: 395-404.
169. Cheetham A, **Lubman DI** (2016). Early onset substance use – a key target for prevention and early intervention. *Addiction*; **111**: 165-166.
170. Peacock A, Droste N, Pennay A, Miller P, **Lubman DI** & Bruno R (2016). Awareness of energy drink intake guidelines and associated consumption practices: A cross-sectional study. *BMC Public Health*; **16**: 6.
171. Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, **Lubman DI** & Solowij N (2016). Hippocampal harms, protection and recovery following regular cannabis use. *Translational Psychiatry*; **6**, e710.
172. Loton D & **Lubman DI** (2016). Just one more level: Identifying and addressing internet gaming disorder within primary care. *Australian Family Physician*; **45**: 48-52.
173. Dowling NA, Youssef GJ, Jackson AC, Pennay DW, Francis KL, Pennay A & **Lubman DI** (2016). National estimates of Australian gambling prevalence: findings from a dual-frame omnibus survey. *Addiction*; **111**: 420-435.

174. Berends L, Garfield JB, Manning V, Buykx P, Lam T, Mugavin J, Larner A, Room R, Allsop S & **Lubman DI** (2016). Social disadvantage and past treatment among clients entering public alcohol and drug services in two Australian states. *International Journal of Drug Policy*; **29**: 88-90.
175. Ogeil RP, Heilbronn C, Lloyd & **Lubman DI** (2016). Prescription drug monitoring in Australia: capacity and coverage issues. *Medical Journal of Australia*; **204**: 148.
176. Garfield J, Cotton S & **Lubman DI** (2016). Psychometric properties, validity, and reliability of the Temporal Experience of Pleasure Scale state version in an opioid-dependent sample. *Drug and Alcohol Dependence*; **161**: 238-246.
177. McKetin R, Gardner J, Baker AL, Dawe S, Ali R, Voce A, Leach LS & **Lubman DI** (2016). Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. *Psychiatry Research*; **238**: 166-171.
178. Hall K, Staiger PK, Simpson A, Best D & **Lubman DI** (2016). After 30 years of dissemination, have we achieved sustained practice change in motivational interviewing? *Addiction*; **111**, 1144–1150.
179. Hall K, Staiger PK, Simpson A, Best D & **Lubman DI** (2016). Continuing the conversation: 30 years of motivational interviewing dissemination. *Addiction*; **111**, 1158–1159.
180. Ogeil RP, Lloyd B, Lam T, Lenton S, Burns L, Aiken A, Gilmore W, Chikritzhs T, Mattick R, Allsop S & **Lubman DI** (2016). Pre-drinking behaviour of young heavy drinkers. *Substance Use and Misuse*; **51**: 1297-1306.
181. **Lubman DI**, Garfield JBB, Manning V, Berends L, Best D, Mugavin JM, Lam T, Buykx P, Larner A, Lloyd B, Room R & Allsop S (2016). Characteristics of individuals presenting to treatment for primary alcohol problems versus other drug problems in the Australian Patient Pathways study. *BMC Psychiatry*; **16**: 250.
182. McCann TV, Mugavin J, Renzaho A & **Lubman DI** (2016). Sub-Saharan African migrant youths' help-seeking barriers and facilitators for mental health and substance misuse problems: a qualitative study. *BMC Psychiatry*; **16**: 275.
183. Arunogiri S & **Lubman DI** (2016). Addressing sedative dependence: Principles for practice. *Australian Clinical Psychologist*; **2**: 20104.
184. Droste N, Miller P, Pennay AE, Zinkiewicz L & **Lubman DI** (2016). Environmental contexts of combined alcohol and energy drink use: associations with intoxication in licensed venues. *International Journal of Drug Policy*; **36**: 58-66.
185. **Lubman DI**, Berridge BJ, Blee F, Jorm AF, Wilson CJ, Allen NB, McKay-Brown L, Priomos J, Cheetham A & Wolfe R (2016). A school-based health promotion programme to increase help-seeking for substance use and mental health problems: study protocol for a randomised controlled trial. *Trials*; **17**: 393.
186. Loton D, Borkoles E, **Lubman DI** & Polman R (2016). Video game addiction, engagement and symptoms of stress, depression and anxiety: The mediating role of coping. *International Journal of Mental Health and Addiction*; **14**: 565-578.
187. Best D, Beckwith M, Haslam C, Haslam S, Jetten J, Mawson E, Savic M & **Lubman DI** (2016). Overcoming alcohol and other drug addiction as a process of social identity transition: the Social Identity Model of Recovery (SIMOR). *Addiction Research and Theory*; **24**: 111-123.
188. Manning V, Staiger P, Hall K, Garfield JBB, Flaks G, Leung D, Hughes LK, Lum JAG, **Lubman DI**, & Verdejo-Garcia A (2016). Cognitive bias modification training during inpatient alcohol detoxification reduces early relapse: A randomised controlled trial. *Alcoholism: Clinical and Experimental Research*; **40**; 2011-2019.
189. Best D, Savic M, Mugavin J, Manning V & **Lubman DI** (2016). Engaging with 12-step and other mutual aid groups during and after treatment: Addressing workers' negative beliefs and attitudes through training. *Alcoholism Treatment Quarterly*; **34**: 303-314.

190. Chien WT, Thompson DR, **Lubman DI** & McCann TV (2016). A randomized controlled trial of clinician-supported problem-solving bibliotherapy for family caregivers of people with first-episode psychosis. *Schizophrenia Bulletin*; **42**: 1457-1466.
191. Droste N, Pennay AE, **Lubman DI**, Zinkiewicz L, Peacock A & Miller P (2016). The right place at the right time: The social contexts of combined alcohol and energy drink use. *Drugs: Education, Prevention & Policy*; **23**: 445-456.
192. Peacock A, Norman T, Bruno R, Pennay A, Droste N, Jenkinson R, Quinn B, **Lubman DI** & Miller P (2016). Typology of alcohol consumers in five Australian night-time entertainment districts. *Drug and Alcohol Review*; **35**: 539-548.
193. Barker SF, Best D, Manning V, Savic M, **Lubman DI** & Rush B (2016). A tiered model of substance use severity and life complexity: Potential for application to needs-based planning. *Substance Abuse*; **37**: 526-533.
194. Best D, Haslam C, Staiger P, Dingle G, Savic M, Bathish R, Mackenzie J, Beckwith M & **Lubman DI** (2016). Social Networks and Recovery (SONAR): Characteristics of a longitudinal outcome study in five therapeutic communities in Australia. *The International Journal of Therapeutic Communities*; **37**: 112-120.
195. Naim-Feil J, Bradshaw JL, Rogasch NC, Daskalakis ZJ, Sheppard DM, **Lubman DI** & Fitzgerald PB (2016). Cortical inhibition within motor and frontal regions in alcohol dependence post-detoxification: A pilot TMS-EEG study. *World Journal of Biological Psychiatry*; **17**: 547-556.
196. Savic M, Barker SF, Hunter B & **Lubman DI** (2016). 'Holy shit, didn't realise my drinking was high risk': an analysis of the way risk is enacted through an online alcohol and drug screening intervention. *Health, Risk & Society*; **17**: 565-591.
197. Mawson E, Best D & **Lubman DI** (2016). Associations between social identity diversity, compatibility, and recovery capital among young people in substance use treatment. *Addictive Behaviors Reports*; **4**: 70-77.
198. Cheetham A, Allen NB, Whittle S, Simmons J, Yücel M & **Lubman DI** (2017). Orbitofrontal cortex volume and effortful control as prospective risk factors for substance use disorder in adolescence. *European Addiction Research*; **23**: 37-44.
199. Pennay A, Jenkinson R, Quinn B, Droste NT, Peacock A, **Lubman DI** & Miller PG (2017). Investigating differences between drugs used in the Australian night-time economy: demographics, substance use and harm. *Substance Use and Misuse*; **52**: 71-81.
200. Manning V, Verdejo-Garcia A & **Lubman DI** (2017). Neurocognitive impairment in addiction and opportunities for intervention. *Current Opinion in Behavioral Sciences*; **13**: 40-45.
201. Manning V, Garfield JB, Best D, Berends L, Room R, Mugavin J, Larnar A, Lam T, Buykx P, Allsop S & **Lubman DI** (2017). Substance use outcomes following treatment: findings from the Australian Patient Pathways Study. *Australian & New Zealand Journal of Psychiatry*; **51**: 177-189.
202. Best DW & **Lubman DI** (2017). Friends matter but so does their substance use: The impact of social networks on substance use, offending and wellbeing among young people. *Drugs: Education, Prevention and Policy*; **24**: 111-117.
203. Merkouris SS, Rodda SN, Austin D, **Lubman DI**, Harvey P, Battersby M, Cunningham J, Lavis T, Smith D & Dowling NA (2017). GAMBLINGLESS. FOR LIFE study protocol: A pragmatic randomised trial of an online cognitive-behavioural program for disordered gambling. *BMJ Open*; **7**: e014226.
204. Droste N, Peacock A, Bruno R, Pennay A, Zinkiewicz L, **Lubman DI** & Miller P (2017). Combined use of alcohol and energy drinks: dose relationship with self-reported physiological stimulation and sedation side effects. *Addictive Behaviors*; **71**: 68-74.

205. Albrecht B, Staiger P, Best D, Hall K, Nielsen S, **Lubman DI** & Miller P (2017). Benzodiazepine use of community-based violent offenders: A preliminary investigation. *Journal of Substance Use*; **22**: 295-303.
206. Lam T, Lenton S, Ogeil R, Chikritzhs T, Gilmore W, Aiken A, Burns L, Lloyd B, Wilson J, **Lubman DI**, Mattick RP & Allsop S (2017). Most recent risky drinking session with Australian teenagers. *Australian & New Zealand Journal of Public Health*; **41**: 105-110.
207. McKetin R, Baker AL, Dawe S, Voce A & **Lubman DI** (2017). Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. *Psychiatry Research*; **251**: 349-354.
208. Savic M, Best D, Manning V & **Lubman DI** (2017). Strategies to facilitate integrated care for people with alcohol and drug problems: a systematic review. *Substance Abuse Treatment, Prevention & Policy*; **12**: 19.
209. Barker SF, Manning V, Best D, Savic M & **Lubman DI** (2017). Alcohol, drug and related health and wellbeing issues among young people completing an online screen. *Australasian Psychiatry*; **25**: 130-134.
210. Rodda SN, **Lubman DI**, Jackson AC & Dowling NA (2017). Improved outcomes following a single session web-based intervention for problem gambling. *Journal of Gambling Studies*; **33**: 283-299.
211. Manning V, Best D, Garfield JBB, Allsop S, Berends L & **Lubman DI** (2017). Money well-spent: Further evidence of improved outcomes for methamphetamine users following treatment. *Drug and Alcohol Review*; **36**: E1-E3.
212. Bathish R, Best D, Savic M, Beckwith M, Mackenzie J & **Lubman DI** (2017). 'Is it me or should my friends take the credit?' The role of social networks and social identity in recovery from addiction. *Journal of Applied Social Psychology*; **47**: 35-46.
213. Ferguson N, Savic M, Manning V & **Lubman DI** (2017). #WaysToRelax: Developing an online health promotion animation for people aged 55+ who are worried about their alcohol use. *Public Health Research & Practice*; **27**: 2721718.
214. Garfield J, Cotton SM, Allen NB, Cheetham A, Kras M, Yücel M & **Lubman DI** (2017). Evidence that anhedonia is a symptom of opioid dependence associated with recent use. *Drug and Alcohol Dependence*; **177**: 29-38.
215. Garde EL, Manning V & **Lubman DI** (2017). Characteristics of clients currently accessing a national online alcohol and drug counselling service. *Australasian Psychiatry*; **25**: 250-253.
216. Wilson SR, Rodda S, **Lubman DI**, Manning V & Yap MBH (2017). How online counselling can support partners of individuals with problem alcohol or other drug use. *Journal of Substance Abuse Treatment*; **78**: 56-62.
217. McCann T, **Lubman DI**, Boardman G & Flood M (2017). Affected family members' experience of, and coping with, aggression and violence within the context of problematic substance use: a qualitative study. *BMC Psychiatry*; **17**: 209.
218. Yap M, Cheong T, Zaravinos-Tsakos F, **Lubman DI**, & Jorm A (2017). Modifiable parenting factors associated with adolescent alcohol misuse: A systematic review and meta-analysis of longitudinal studies. *Addiction*; **112**: 1142-1162.
219. McCann TV, Cotton S & **Lubman DI** (2017). Social problem-solving in carers of young people with a first episode of psychosis: a randomised controlled trial. *Early Intervention in Psychiatry*; **11**: 346-350.
220. Yücel M, Carter A, Allen A, Balliene B, Clark L, Dowling N, Gainsbury S, Goudriaan A, Grant J, Hayes A, Hodgins D, van Holst R, Lattimore R, Livingstone C, Lorenzetti V, **Lubman DI**, Murawski C, Parkes L, Petry N, Room R, Singh B, Thomas A, Townshend P, Youssef G & Hall W (2017). The role for neuroscience in gambling policy and treatment: An interdisciplinary perspective. *Lancet Psychiatry*; **4**: 501-506.

221. Arunogiri S, Petrie M, Sharkey M & **Lubman DI** (2017). Key differences in treatment-seeking stimulant users attending a specialised treatment service: a means of early intervention? *Australasian Psychiatry*; **25**: 246-249.
222. Witt K, **Lubman DI**, Lloyd B & Smith K (2017). Co-consumption of alcohol and psychotropic medications in episodes of non-fatal self-poisoning attended by ambulance services in Victoria, Australia: Evidence of potential modification by medical severity (eLetter). *British Journal of Psychiatry*; **211**: 53.
223. Foulds JA & **Lubman DI** (2017). Treating depression in patients with alcohol or drug use disorders: a need for clearer guidelines. *Australian & New Zealand Journal of Psychiatry*; **51**: 668-669.
224. Beatson J, Broadbear JH, **Lubman DI** & Rao S (2017). Hallucinations in BPD: more prevalent than community sample study suggests? (eLetter) *British Journal of Psychiatry*; **211**: 250-251.
225. Savic M, Ferguson N, Manning V, Bathish R & **Lubman DI** (2017). “What constitutes a ‘problem?’”. Producing ‘alcohol problems’ through online counselling encounters. *International Journal of Drug Policy*; **46**: 79-89.
226. **Lubman DI**, Cheetham A, Jorm AF, Berridge BJ, Wilson C, Blee F, McKay-Brown L, Allen NB & Proimos J (2017). Australian adolescents' attitudes and help-seeking intentions towards peers experiencing symptoms of depression and alcohol misuse. *BMC Public Health*; **17**: 658.
227. **Lubman DI**, Cheetham A, Blee F, Berridge BJ & McKay-Brown L (2017). Australian adolescents' understanding of confidentiality in mental health (letter). *Australian & New Zealand Journal of Psychiatry*; **51**: 942-944.
228. Lloyd B, Zahnow R, Barratt MJ, Best D, **Lubman DI** & Ferris J (2017). Exploring mortality among drug treatment clients: the relationship between treatment type and mortality. *Journal of Substance Abuse Treatment*; **82**: 22-28.
229. Arunogiri S & **Lubman DI** (2017). Challenges in reviewing methamphetamine-associated psychosis (eLetter). *BMJ Open*; **7**: e015383.
230. Cheetham A & **Lubman DI** (2017). The role of peers in school-based prevention programs targeting adolescent substance use. *Current Addiction Reports*; **4**: 379-385.
231. Kras M, Youssef GJ, Garfield JB, Yücel M, **Lubman DI** & Stout J (2018). Relationship between measures of impulsivity in opioid-dependent individuals. *Personality and Individual Differences*; **120**: 133-137.
232. Rodda SN, Hing N, Hodgins DC, Cheetham A, Dickins M & **Lubman DI** (2017). Change strategies and associated implementation challenges: An analysis of online counselling sessions. *Journal of Gambling Studies*; **33**: 955-973.
233. Lee-Tobin PA, Ogeil RP, Savic M & **Lubman DI** (2017). Rate my sleep: examining the information, function, and basis in empirical evidence within sleep applications for mobile devices. *Journal of Clinical Sleep Medicine*; **13**: 1349-1354.
234. Murphy A, **Lubman DI**, McKie S, Bijral PS, Peters LA, Faiz Q, Holmes S, Anderson I, Deakin B & Elliott R (2017). Time-dependent neuronal changes associated with craving in opioid dependence: an fMRI study. *Addiction Biology*; **23**: 1168-1178.
235. Wilson J, Ogeil RP, Lam T, Lenton S, Lloyd B, Burns L, Aiken A, Gilmore W, Chikritzhs T, Mattick R, **Lubman DI** & Allsop S (2017). Re-thinking pre-drinking: Implications from a sample of teenagers who drink in private settings. *International Journal of Drug Policy*; **52**: 20-24.
236. Manning V, Dowling NA, Lee S, Rodda S, Garfield JBB, Volberg R, Kulkarni J & **Lubman DI** (2017). Problem gambling and substance use in patients attending community mental health services. *Journal of Behavioral Addictions*; **6**: 678-688.

237. Savic M, Dilkes-Frayne E, Carter A, Kokanovic R, Manning V & **Lubman DI** (2018). Making multiple 'online counsellings' through policy and practice: an evidence-making intervention approach. *International Journal of Drug Policy*; **53**: 73-82.
238. Rodda S, Dowling NA, Knaebe B & **Lubman DI** (2018). Does SMS improve gambling outcomes over and above access to other e-mental health supports? A feasibility study. *International Gambling Studies*; **18**: 343-357.
239. Berridge BJ, McCann TV, Cheetham A & **Lubman DI** (2018). Perceived barriers and enablers of help-seeking for substance use problems during adolescence. *Health Promotion Practice*; **19**: 86-93.
240. McCann TV & **Lubman DI** (2018). Adaptive coping strategies of affected family members of a relative with substance misuse: a qualitative study. *Journal of Advanced Nursing*; **1**: 100-109.
241. Poole LA, Knight T, Toumbourou JW, **Lubman DI**, Bertino MD & Lewis AJ (2018). A randomized controlled trial of the impact of a family-based adolescent depression intervention on both parent and youth mental health outcomes. *Journal of Abnormal Child Psychology*; **46**: 169-181.
242. McKetin R, Kothe A, Baker A, Lee, NK, Ross J & **Lubman DI** (2018). Predicting abstinence from methamphetamine use after residential rehabilitation: findings from the Methamphetamine Treatment Evaluation Study (MATES). *Drug & Alcohol Review*; **37**: 70-78.
243. McKetin R, Degenhardt L, Shanahan M, Baker AL, Lee NK & **Lubman DI** (2018). Health service utilisation attributable to methamphetamine use in Australia: patterns, predictors and national impact. *Drug & Alcohol Review*; **37**: 196-204.
244. Pennay A, McNair R, Hughes TL, Leonard W, Brown R & **Lubman DI** (2018). Improving alcohol and mental health treatment for lesbian, bisexual and queer women: Identity matters. *Australian & New Zealand Journal of Public Health*; **42**: 35-42.
245. Ogeil RP, Dwyer J, Bugeja L, Heilbronn C, **Lubman DI** & Lloyd B (2018). Pharmaceutical opioid overdose deaths and the presence of witnesses. *International Journal of Drug Policy*; **55**: 8-13.
246. Rodda S, Manning V, Dowling NA, Lee SJ & **Lubman DI** (2018). Barriers and facilitators of responding to problem gambling: Perspectives from Australian mental health services. *Journal of Gambling Studies*; **34**: 307-320.
247. Ruben AJ, Fitzpatrick RE, **Lubman DI** & Verdejo-Garcia A (2018). Impulsivity predicts poorer improvement in quality of life during early treatment for people with methamphetamine dependence. *Addiction*; **113**: 668-676.
248. McCann T & **Lubman DI** (2018). Stigma experience of families supporting an adult member with substance misuse. *International Journal of Mental Health Nursing*; **27**: 693-701.
249. Curtis A, Youssef G, Guadagno B, Manning V, Enticott PG, **Lubman DI** & Miller PG (2018). Swift, certain, and fair justice: insights from behavioural learning and neurocognitive research. *Drug & Alcohol Review*; **37**: S240-S245.
250. McCann TV, Renzaho A, Mugavin J & **Lubman DI** (2018). Stigma of mental disorder and substance misuse in sub-Saharan African migrants: a qualitative study. *International Journal of Mental Health Nursing*; **27**: 956-965.
251. Dowling NA, Merkouris SS, Manning V, Volberg R, Lee SJ, Rodda SN & **Lubman DI** (2018). Screening for problem gambling within mental health services: A comparison of the classification accuracy of brief instruments. *Addiction*; **113**: 1088-1104.
252. Hodges CJ, Ogeil RP & **Lubman DI** (2018). The effects of acute alcohol withdrawal on sleep. *Human Psychopharmacology: Clinical and Experimental*; **33**: e2657.

253. Cheetham A, Allen NB, Whittle S, Simmons J, Yücel M & **Lubman DI** (2018). Amygdala volume mediates the relationship between externalizing symptoms and daily smoking in adolescence: a prospective study. *Psychiatry Research: Neuroimaging*; **276**: 46-52.
254. Aiken A, Lam T, Gilmore W, Burns L, Chikritzhs T, Lenton S, Lloyd B, **Lubman DI**, Ogeil R & Allsop S (2018). Youth perceptions of alcohol advertising: Are current advertising regulations working? *Australian & New Zealand Journal of Public Health*; **42**: 234-239.
255. Witt K & **Lubman DI** (2018). Effective suicide prevention: Where is the discussion on alcohol? *Australian & New Zealand Journal of Psychiatry*; **52**: 507-508.
256. Arunogiri S, Foulds JA, McKetin R & **Lubman DI** (2018). A systematic review of risk factors for methamphetamine-associated psychosis. *Australian & New Zealand Journal of Psychiatry*; **52**: 514-529.
257. Crossin R, Scott D, Witt KG, Duncan JR, Smith K & **Lubman DI** (2018). Acute harms associated with inhalant misuse: co-morbidities and trends relative to age and gender among ambulance attendees. *Drug and Alcohol Dependence*; **190**: 46-53.
258. McKetin R, **Lubman DI**, Baker A, Dawe S, Ross J, Mattick R & Degenhardt L (2018). The relationship between methamphetamine use and heterosexual behaviour: Evidence from a prospective longitudinal study. *Addiction*; **113**: 1276-1285.
259. Scott D, Crossin R, Ogeil R, Smith K & **Lubman DI** (2018). Exploring harms experienced by children aged 7 to 11 using ambulance attendance data: a 6-year comparison with adolescents aged 12-17. *International Journal of Environmental Research and Public Health*; **15**: 1385.
260. Guillaumier A, Manning V, Wynne O, Gartner C, Borland R, Baker A, Segan CJ, Skelton E, Moore L, Bathish R, **Lubman DI** & Bonevski B (2018). Electronic nicotine devices to aid smoking cessation by alcohol- and drug-dependent clients: protocol for a pilot randomised controlled trial. *Trials*; **19**: 415.
261. McCann T & **Lubman DI** (2018). Help-seeking barriers and facilitators for affected family members of a relative with alcohol and other drug misuse: A qualitative study. *Journal of Substance Abuse Treatment*; **93**: 7-14.
262. Foulds J, Manning V, Garfield JBB, Allsop SJ, Lam T, Arunogiri S & **Lubman DI** (2018). Prescribed sedative and other psychotropic medication use among clients attending alcohol and other drug treatment. *Drug and Alcohol Review*; **37**: 738-742.
263. **Lubman DI**, Garfield JBB, Gwini SM, Cheetham A, Cotton SM, Yücel M & Allen NB (2018). Dynamic associations between opiate use and reported anhedonia: A longitudinal study in opiate dependence. *Journal of Psychopharmacology*; **32**: 957-964.
264. Rodda SN, Dowling NA & **Lubman DI** (2018). Gamblers seeking help online are active help-seekers: Time to support autonomy and competence. *Addictive Behaviors*; **87**: 272-275.
265. Ogeil RP, Barger LK, Lockley SW, O'Brien CS, Sullivan JP, Qadri S, **Lubman DI**, Czeisler CA & Rajaratnam SMW (2018). Cross-sectional analysis of sleep-promoting and wake-promoting drug use on health, fatigue-related error, and near-crashes in police officers. *BMJ Open*; **8**: e022041.
266. Cheetham A & **Lubman DI** (2018). Adolescents who seek help for depression report greater lifetime use of alcohol and increased experience of alcohol-related problems (letter). *Australian & New Zealand Journal of Psychiatry*; **52**: 902-903.
267. Rodda SN, Bagot KL, Cheetham A, Hodgins DC, Hing N & **Lubman DI** (2018). Types of change strategies for limiting or reducing gambling behaviours and their perceived helpfulness: A factor analysis. *Psychology of Addictive Behavior*; **32**: 679-688.
268. Savic M & **Lubman DI** (2018). An argument against the implementation of an 'overarching universal addiction model' in alcohol and other drug treatment. *Drug and Alcohol Review*; **37**: 721-722.

269. **Lubman DI**, Cheetham A, Berridge B & McKay-Brown L (2018). MAKINGtheLINK: A school-based intervention to improve help-seeking for substance use problems. *Early Intervention in Psychiatry*; **12**: 915-921.
270. Wilson SR, **Lubman DI**, Rodda S, Manning V & Yap MBH (2018). The personal impacts of having a partner with problematic alcohol or other drug use: Descriptions from online counselling sessions. *Addiction Research and Theory*; **26**: 315-322.
271. Pennay A, Peacock A, Droste N, Miller P, Graeme P, Bruno R, Wadds P, Tomsen S & **Lubman D** (2018). What do we know about alcohol mixed with energy drink (AmED) use in Australia? Expanding local evidence. *Public Health Research & Practice*; **28**: e2831817.
272. Butler M, Savic M, Best D, Manning V, Mills KL & **Lubman DI** (2018). Wellbeing and coping strategies of alcohol and other drug therapeutic community workers: a qualitative study. *Therapeutic Communities*; **39**: 118-128.
273. Rubenis AJ, Fitzpatrick RE, **Lubman DI** & Verdejo-Garcia A (2018). Sustained attention but not effort-based decision-making predicts treatment motivation change in people with methamphetamine dependence. *Journal of Substance Abuse Treatment*; **95**: 48-54.
274. Rodda SN, Hing N, Hodgins DC, Cheetham A, Dickins M & **Lubman DI** (2018). Behaviour change strategies for problem gambling: An analysis of online posts. *International Gambling Studies*; **18**: 420-438.
275. Manning V, Campbell SC, Garfield JBB, Reynolds J, Staiger PK, Hall K, Lum JAG, Wiers R, **Lubman DI** & Verdejo-Garcia A (2018). Protocol for a randomised controlled trial of cognitive bias modification training during inpatient withdrawal from alcohol use disorder. *Trials*; **19**: 598.
276. McCann TV, Savic M, Fergusson N, Cheetham A, Witt K, Emond K, Bosley E, Smith K, Roberts L & **Lubman DI** (2018). Recognition of, and attitudes toward, people with depression and psychosis with/without alcohol and other drug problems: results from a national survey of Australian paramedics. *BMJ Open*; **8**: e023860.
277. Elms E, Savic M, Bathish R, Best D, Manning V & **Lubman DI** (2018). Multiple pathways to recovery, multiple roads to wellbeing: an analysis of recovery pathways in the Australian Life in Recovery survey. *Alcoholism Treatment Quarterly*; **36**: 482-498.
278. McKetin R, Voce A, Burns R, Ali R, **Lubman DI**, Baker AL & Castle DJ (2018). Latent psychotic symptom profiles amongst people who use methamphetamine: what do they tell us about existing diagnostic categories? *Frontiers in Psychiatry*; **19**: 578.
279. Lam T, Ogeil R, Allsop S, Chikritzhs T, Fischer J, Midford R, Gilmore W, Lenton S, Liang W, Lloyd L, Aiken A, Mattick R, Burns L & **Lubman DI** (2018). Insomnia and regulation of sleep-wake cycle with drugs among adolescent risky drinkers. *Journal of Clinical Sleep Medicine*; **14**: 1529-1537.
280. McCann T, Savic M, Ferguson N, Bosley E, Smith K, Roberts L, Emond K & **Lubman DI** (2018). Paramedics' perceptions of their scope of practice in caring for patients with non-medical emergency-related mental health and/or alcohol and other drug problems: a qualitative study. *PLoS ONE*; **13**: e0208391.
281. Hall K, Simpson A, Staiger P, Morton J, Ryan D, Sloan E, Nunn B, Best D & **Lubman DI** (2018). Emotional dysregulation as a target in the treatment of co-existing substance use and borderline personality disorders: a pilot study. *Clinical Psychologist*; **22**: 112-125.
282. McNair R, Pennay A, Hughes T, Love S, Valpied J & **Lubman DI** (2018). Health service use by same-sex attracted Australian women for alcohol and mental health issues: a cross-sectional study. *British Journal of General Practice Open*; **2**: 18X101565.
283. Witt K, Daly C, Arensman E, Pirkis J & **Lubman DI**. (2019). Patterns of self-harm methods over time and the association with methods used at repeat episodes of non-fatal self-harm and suicide: A systematic review. *Journal of Affective Disorders*; **245**: 250-264.

284. Grigg J, Manning V, Arunogiri S & **Lubman DI** (2019). Synthetic cannabinoid use disorder: an update for general psychiatrists. *Australasian Psychiatry*; **27**: 279-283.
285. Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM & **Lubman DI** (2019). Pregabalin misuse-related ambulance attendances in Victoria, 2012-2017: characteristics of patients and attendances. *Medical Journal of Australia*; **210**: 75-79.
286. Xia T, Iles R, Newnam S, **Lubman DI** & Collie A (2019). Work-related injury and disease in Australian transport sector workers: A retrospective population based cohort study. *Journal of Transport & Health*; **12**: 34-41.
287. Arunogiri S, Crossin R, Scott D & **Lubman DI** (2019). Monitoring emerging prescription-drug related harms: a comment on Cairns et al. (2018). *Addiction*; **114**: 571-572.
288. McCann TV, Stephenson J & **Lubman DI** (2019). Affected family member coping with a relative with alcohol and/or other drug misuse: A cross-sectional survey questionnaire. *International Journal of Mental Health Nursing*; **28**: 687-696.
289. Rubenis AJ, Fitzpatrick RE, **Lubman DI** & Verdejo-Garcia A (2019). Working memory predicts methamphetamine hair concentration over the course of treatment: Moderating effect of impulsivity and implications for the dual-systems model. *Addiction Biology*; **24**: 145-153.
290. Pennay A, Callinan S, Livingston M, **Lubman DI**, Holmes J, MacLean S, Herring R & Dietze P (2019). Patterns in reduction or cessation of drinking in Australia (2001-2013) and motivation for change. *Alcohol & Alcoholism*; **54**: 79-86.
291. Gilmartin-Thomas JF, Simon Bell J, Liew D, Arnold CA, Buchbinder R, Chapman C, Cicuttini F, Dobbin M, Gibson SJ, Giummarra MJ, Gowan J, Katz B, **Lubman DI**, McCrone M, Pilgrim J, Synnot A, van Dyk E, Workman B, McNeil J (2019). Chronic pain medication management of older populations: key points from a national conference and innovative opportunities for pharmacy practice. *Research in Social and Administrative Pharmacy*; **15**: 207-213.
292. Dodd S, Arancini L, Gómez-Coronado N, Gasser R, **Lubman DI**, Dean OM & Berk M (2019). Considerations when selecting pharmacotherapy for nicotine dependence. *Expert Opinion on Pharmacotherapy*; **20**: 245-250.
293. Knaebe K, Rodda SN, Hodgins DC & **Lubman DI** (2019). Behaviour change strategies endorsed by gamblers subtyped by psychological distress, risky alcohol use, and impulsivity. *Journal of Gambling Studies*; **35**: 275-292.
294. Bush R, Brown R, McNair R, Orellana L, **Lubman DI** & Staiger PK (2019). Effectiveness of a culturally tailored SMS alcohol intervention for same-sex attracted women: Protocol for an RCT. *BMC Women's Health*; **19**: 29.
295. Wilson SR, **Lubman DI**, Rodda S, Manning V & Yap MBH (2019). The impact of problematic substance use on partners' interpersonal relationships: Qualitative analysis of counselling transcripts from a national online service. *Drugs: Education, Prevention & Policy*; **26**: 429-436.
296. Ogeil R, Cheetham A, Mooney A, Allen NB, Schwartz O, Byrne M, Simmons JG, Whittle S, **Lubman DI** (2019). Early adolescent drinking and cannabis use predicts later sleep quality problems. *Psychology of Addictive Behaviors*; **33**: 266-273.
297. Haslam C, Best D, Dingle GA, Staiger PK, Savic S, Bathish R, Mackenzie J, Beckwith M, Kelly AJ & **Lubman DI** (2019). Social group membership before treatment for substance dependence predicts early identification and engagement with treatment communities. *Addiction Research & Theory*; **27**: 363-372.
298. Ferguson N, Savic M, McCann TV, Emond K, Sandral E, Smith K, Roberts L, Bosley E & **Lubman DI** (2019). "I was worried if I don't have a broken leg they might not take it so seriously": Experiences of men accessing ambulance services for mental health and/or alcohol and other drug problems. *Health Expectations*; **22**: 565-574.

299. Nielsen S, Crossin R, Middleton M, Martin C, Wilson J, Lam T, Scott D, Smith K & **Lubman DI** (2019). Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study. *BMJ Open*; **9**: e029170.
300. Manning V, Mroz K, Garfield JBB, Staiger PK, Hall K, **Lubman DI** & Verdejo-Garcia A (2019). Combining approach bias modification with working memory training during inpatient alcohol withdrawal: An open-label pilot trial of feasibility and acceptability. *Substance Abuse Treatment, Prevention, and Policy*; **14**: 24.
301. Cheetham A, Jorm AF, Wilson C, Berridge BJ, Blee F & **Lubman DI** (2019). Stigmatising attitudes towards depression and alcohol misuse in young people: relationships with help-seeking intentions and behavior. *Adolescent Psychiatry*; **9**: 24-32.
302. McKetin R, Dean OM, Turner A, Kelly PJ, Quinn B, **Lubman DI**, Dietze P, Carter G, Higgs P, Baker AL, Sinclair B, Reid D, Manning V, te Pas N, Liang W, Thomas T, Bathish R, Kent M, Raftery D, Arunogiri S, Cordaro F, Hill H & Berk M (2019). A study protocol for the N-ICE trial: A randomized double-blind placebo-controlled study of the safety and efficacy of N-Acetyl-Cysteine (NAC) as a pharmacotherapy for methamphetamine (“ice”) dependence. *Trials*; **20**: 325.
303. Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, Egerton-Warburton D, Karro J, Kim C, Lenton S, **Lubman DI**, Pastor A, Rundle J, Ryan J, Gordon P, Sharry P, Nutt D & Castle D (2019). The Australian Drug Harms Ranking Study. *Journal of Psychopharmacology*; **33**: 759-768.
304. Lalic S, Jokanovic N, Ilomäki J, Gisev N, Lloyd B, **Lubman DI** & Bell S (2019). Harms associated with extramedical use of prescription opioid analgesics in Australia: a scoping review. *Research in Social and Administrative Pharmacy*; **15**: 925-935.
305. **Lubman DI**, Grigg J, Manning V, Hall K, Volpe I, Dias S, Baker A, Staiger P, Reynolds J, Harris A, Tyler J & Best D (2019). A structured telephone-delivered intervention to reduce problem alcohol use (Ready2Change): study protocol for a parallel group randomised controlled trial. *Trials*; **20**: 515.
306. Ogeil RP, Phillips JG, Savic M & **Lubman DI** (2019). Sleep- and wake-promoting drugs: where are they being sourced, and what is their impact? *Substance Use & Misuse*; **33**: 759-768.
307. Rodda SN, Bagot KL, Manning V & **Lubman DI** (2019). "Only take the money you want to lose". Strategies for sticking to limits in electronic gaming machine venues. *International Gambling Studies*; **19**: 489-507.
308. Smith CM, Garfield JBB, Attawar A, **Lubman DI** & Lawrence AJ (2019). The influence of opioid dependence on salt consumption and related psychological parameters in mice and humans. *Drug and Alcohol Dependence*; **203**: 19-26.
309. Dingle GA, Haslam C, Best D, Chan G, Staiger PK, Savic M, Beckwith M, Mackenzie J, Bathish R & **Lubman DI** (2019). Social identity differentiation predicts commitment to sobriety and wellbeing in residents of therapeutic communities. *Social Society & Medicine*; **237**: 112459.
310. Manning V, Garfield JBB, Mroz K, Campbell SC, Piercy H, Staiger PK, Lum JAG, **Lubman DI** & Verdejo-Garcia A (2019). Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes. *Journal of Substance Abuse Treatment*; **106**: 12-18.
311. Manning V, Garfield JBB, Lam T, Allsop S, Berends L, Best D, Buykx P, Room R & **Lubman DI** (2019). Improved quality of life following addiction treatment is associated with reductions in substance use. *Journal of Clinical Medicine*; **8**: 9.
312. Dilkes-Frayne E, Savic M, Carter A, Kokanović R & **Lubman DI** (2019). Going online: The affordances of online counselling for families affected by alcohol and other drug issues. *Qualitative Health Research*; **29**: 2010-2022.

313. Rodda SN, Merkouris S, Lavis T, Smith D, **Lubman DI**, Austin D, Harvey P, Battersby M & Dowling NA (2019). The therapist experience of internet delivered CBT for problem gambling: Service integration considerations. *Internet Interventions*; **18**: 100264.
314. Beckwith M, Best D, Savic M, Haslam C, Bathish R, Dingle G, Staiger PK, Mackenzie J & **Lubman DI** (2019). Social Identity Mapping in Addiction Recovery (SIM-AR): Extension and application of a visual method. *Addiction Research & Theory*; **27**: 462-471.
315. Lam T, Laslett AM, Ogeil RP, **Lubman DI**, Liang W, Chikritzhs TN, Gilmore WG, Lenton SR, Fischer J, Aiken A, Mattick RP, Burns LA, Midford R & Allsop SJ (2019). From eye rolls to punches: experience of harm from others' drinking amongst risky drinking adolescents across Australia. *Public Health Research & Practice*; **29**: 2941927.
316. Rodda S, Bagot K, Manning V & **Lubman DI** (2019). "It was terrible. I didn't set a limit": proximal and distal prevention strategies for reducing the risk of a bust in gambling venues. *Journal of Gambling Studies*; **35**: 1407-1421.
317. Liu Y, van den Wildenberg WPM, de Graaf Y, Ames SL, Baldacchino A, Ragnhild B, Cadaveira F, Campanella S, Christiansen P, Claus ED, Colzato LS, Filbey FM, Foxe JJ, Garavan H, Hendershot CS, Hester R, Jester JM, Karoly HC, Kräplin A, Kreuzsch F, Landrø NI, Littel M, Steins-Loeber S, London ED, López-Caneda E, **Lubman DI**, Luijten M, Marcziński CA, Metrik J, Montgomery C, Papachristou H, Mi Park S, Paz AL, Petit G, Prisciandaro JJ, Quednow BB, Ray LA, Roberts CA, Roberts GMP, de Ruiter MB, Rupp CI, Steele VR, Sun D, Takagi M, Tapert SF, Holst RJV, Verdejo-Garcia A, Vonmoos M, Wojnar M, Yao Y, Yücel M, Zack M, Zucker RA, Huizenga HM, Wiers RW (2019). Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders. *Neuroscience & Biobehavioral Reviews*; **105**: 288-304.
318. Coomber K, Curtis A, Vandenberg B, Miller PG, Heilbronn C, Matthews S, Smith K, Wilson J, Moayeri F, Mayshak R, **Lubman DI** & Scott D (2019). Aggression and violence at ambulance attendances where alcohol, illicit and/or pharmaceutical drugs were recorded: a 5-year study of ambulance records in Victoria, Australia. *Drug and Alcohol Dependence*; **205**: 107685.
319. Arunogiri S, Verdejo-Garcia A, McKetin R, Rubenis AJ, Fitzpatrick RE & **Lubman DI** (2019). Emotion recognition and impulsive choice in relation to methamphetamine use and psychosis symptoms. *Frontiers in Psychiatry*; **10**: 889.
320. Savic M, Ogeil R, Sechtig M, Lee-Tobin P, Ferguson N & **Lubman DI** (2019). How do nurses cope with shift work? A qualitative analysis of open-ended responses from a survey of nurses. *International Journal of Environmental Research and Public Health*; **16**: E3821.
321. Donald F, Arunogiri S & **Lubman DI** (2019). Substance use and borderline personality disorder: fostering hope in the face of complexity. *Australasian Psychiatry*; **27**: 569-572.
322. McCann TV, Polacsek M & **Lubman DI** (2019). Experiences of family members supporting a relative with substance use problems: a qualitative study. *Scandinavian Journal of Caring Sciences*; **33**: 902-911.
323. Dowling NA, Merkouris SS, Dias S, Rodda SN, Manning V, Youssef GJ, **Lubman DI** & Volberg RA (2019). The diagnostic accuracy of brief screening instruments for problem gambling: A systematic review and meta-analysis. *Clinical Psychology Review*; **74**: 101784.
324. Oakes J, Pols R, Lawn S, Battersby M & **Lubman DI** (2019). "I'll just pay the rent next month": An exploratory study examining facilitatory cognitions among EGM problem gamblers. *International Journal of Mental Health and Addiction*; **17**: 1564-1579.
325. Verdejo-García A, Lorenzetti V, Manning V, Piercy H, Bruno R, Hester R, Pennington D, Tolomeo S, Arunogiri A, Bates NE, Bowden-Jones H, Campanella S, Daughters S, Kouimtsidis C, **Lubman DI**, Meyerhoff DJ, Ralph A, Rezapour T, Tavakoli H, Zare-Bidoky M, Zilverstand A, Steele JD, Moeller SJ, Baldacchino AM, Paulus MP & Ekhtiari H (2019). A roadmap for

- integrating neuroscience into addiction treatment: a consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine. *Frontiers in Psychiatry*; **10**: 877.
326. **Lubman DI**, Cheetham A, Sandral E, Wolfe R, Martin C, Blee F, Berridge BJ, Jorm AF, Wilson C, Allen NB, McKay-Brown L & Proimos J (2020). Twelve-month outcomes of MAKINGtheLINK: a cluster randomized controlled trial of a school-based program to facilitate help-seeking for substance use and mental health problems. *EClinicalMedicine*; **18**: 100225.
327. Best D, Manning V, Allsop S & **Lubman DI** (2020). Does the effectiveness of mutual aid depend on compatibility with treatment philosophies offered at residential rehabilitation services? *Addictive Behaviors*; **103**: 106221.
328. Lorenzetti V, Chye Y, Suo C, Walterfang M, **Lubman DI**, Takagi M, Whittle S, Verdejo-Garcia A, Cousijn J, Pantelis C, Seal M, Fornito A, Yücel M & Solowij N (2020). Neuroanatomical alterations in people with high and low cannabis dependence. *Australian and New Zealand Journal of Psychiatry*; **54**: 68-75.
329. Lam T, Ogeil RP, Fischer J, Midford R, **Lubman DI**, Gilmore W, Chikritzhs T, Liang W, Lenton SR, Aiken A & Allsop S (2020). Alcohol supply as a favour for a friend: Scenarios of alcohol supply to younger friends and siblings. *Health Promotion Journal of Australia*; **31**: 112-120.
330. Ogeil RP, Chakraborty S, Young AC & **Lubman DI** (2020). Clinician and patient barriers to the recognition of insomnia in family practice: A narrative summary of reported literature analysed using the theoretical domains framework. *BMC Family Practice*; **21**: 1.
331. Xia T, Iles R, Newnam S, **Lubman DI** & Collie A (2020). Patterns of health service use following work-related injury and illness in Australian truck drivers: a latent class analysis. *American Journal of Industrial Medicine*; **63**: 180-187.
332. Ogeil R, Witt K, Scott D, Smith K & **Lubman DI** (2020). Self-reported sleep disturbance in ambulance attendances for suicidal ideation and attempted suicide between 2012 and 2017. *Journal of Affective Disorders*; **265**: 364-371.
333. Phan V, Arunogiri S & **Lubman DI**. The assessment and management of gamma hydroxybutyrate use in general practice. *Australian Journal of General Practice*; **49**: 73-78.
334. **Lubman DI**, Matthew S, Heilbronn C, Killian JJ, Ogeil RP, Lloyd B, Witt K, Crossin R, Smith K, Bosely E, Carney R, Wilson A, Eastham M, Keene T, Brook C, Shipp C & Scott D (2020). The National Ambulance Surveillance System: A novel method for monitoring acute alcohol, illicit and pharmaceutical drug related-harms using coded Australian ambulance clinical records. *PLOS One*; **15**: e0228316.
335. Arunogiri S, Moayeri F, Crossin R, Killian JJ, Smith K, Scott D & **Lubman DI** (2020). Trends in GHB-related harms based on ambulance attendances from 2012-2018 in Victoria, Australia. *Addiction*; **115**: 473-479.
336. Fitzpatrick RE, Rubenis AJ, **Lubman DI** & Verdejo-Garcia A (2020). Cognitive deficits in methamphetamine addiction: independent contributions of dependence and intelligence. *Drug & Alcohol Dependence*; **209**: 107891.
337. Armstrong F, Arunogiri S, Frei MY & **Lubman DI** (2020). The six Rs of managing high-risk opioid prescribing. *Australian Journal of General Practice*; **49**: 116-120.
338. Grigg J, Arunogiri S, Manning V, Phan V, Campbell S, Frei M & **Lubman DI** (2020). The Drug and Alcohol Clinical Advisory Service: a model of telephone-delivered addiction specialist support. *Drug & Alcohol Review*; **39**: 238-245.
339. Lam T, Kuhn L, Hayman J, Middleton M, Wilson J, Scott D, **Lubman DI**, Smith K & Nielsen S (2020). Recent trends in heroin and pharmaceutical-opioid related harms in Victoria, Australia up to 2018. *Addiction*; **115**: 261-269.

340. Cheetham A, Sandral E & **Lubman DI** (2020). Outcomes of reducing stigma towards alcohol misuse during adolescence: results of a randomized controlled trial of the MAKINGtheLINK intervention. *Child and Adolescent Psychiatry and Mental Health*; **14**: 11.
341. Grigg J, Killian JJ, Matthews S, Scott D, Arunogiri S, Manning V, Taylor DA, Crossin R, Smith K & **Lubman DI** (2020). The impact of legislation on acute synthetic cannabinoid harms resulting in ambulance attendance. *International Journal of Drug Policy*; **79**: 102720.
342. Arunogiri S, McKetin R, Verdejo-Garcia A & **Lubman DI** (2020). The methamphetamine-associated psychosis spectrum: A clinically focused review. *International Journal of Mental Health and Addiction*; **18**: 54-65.
343. Rodda SN, Bagot KL, Manning V & **Lubman DI** (2020). An exploratory RCT to support gamblers' intentions to stick to monetary limits: A brief intervention using action and coping planning. *Journal of Gambling Studies*; **36**: 387-404.
344. Maltman K, Savic M, Manning V, Dilkes-Frayne E, Carter A & **Lubman DI**. 'Holding On' and 'Letting Go': A thematic analysis of parent's styles of coping with their child's methamphetamine use. *Addiction Research & Theory*; in press.
345. Vashishtha R, Livingston M, Pennay A, Dietze P, MacLean S, Holmes J, Herring R, Caluzzi G & **Lubman DI**. Why is adolescent drinking declining? A systematic review and narrative synthesis. *Addiction Research & Theory*; in press.
346. Rodda SN, Dowling NA, Thomas AC, Bagot K & **Lubman DI**. Treatment for family members of people experiencing gambling problems: Family members want both gambler-focused and family-focused options. *International Journal of Mental Health and Addiction*; in press.
347. Nielsen S, Crossin R, Middleton M, Lam T, Wilson J, Scott D, Martin C, Smith K & **Lubman DI**. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013-2018. *Addiction*; in press.
348. Chong J, Frei M & **Lubman DI**. Managing long-term high-dose prescription opioids in patients with non-cancer pain: the potential role of sublingual buprenorphine. *Australian Journal of General Practice*; in press.
349. McCann TV & **Lubman DI**. Peer mentorship of hospital inpatients with substance use disorders is associated with beneficial outcomes. *Evidence Based Nursing*; in press.
350. Bagot K, Rodda S, Cheetham A & **Lubman DI**. Predictors of strategy engagement for the prevention and reduction of gambling harm: a prospective application of the Theory of Planned Behaviour. *International Journal of Mental Health and Addiction*; in press.
351. Oakes JE, Manning V, Rodda SN & **Lubman DI**. A six-step brief intervention to reduce distress and increase treatment readiness in problem gamblers. *Australasian Psychiatry*; in press.